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Improving NK Cell Therapy for Osteosarcoma 
Jennifer Ann Foltz, M.S. 
Advisory Professor: Dean Lee, M.D. Ph.D. 
 Osteosarcoma (OS) is the most common primary bone tumor. Despite new 
treatment options, 5-year survival for metastatic OS has remained at only 30% for 
the last 30 years. Adoptive transfer of Natural Killer (NK) cells holds promise for a 
new, non-toxic therapy for OS. NK cells are part of the innate immune system and 
readily kill metastatic and chemotherapy-resistant OS in vitro and in murine models. 
However, there is little data regarding their efficacy in animal models with an intact 
immune system. In addition, the OS tumor microenvironment is highly suppressive, 
producing TGFβ which impedes NK cell killing of solid tumors. We set out to 
overcome these hurdles by characterizing NK cells in the canine model, which 
spontaneously develops OS, has a complete tumor microenvironment, an intact 
immune system, and is an established animal model with proven translatability to 
human OS. However, little is known about canine NK, preventing the testing of NK 
cell therapy in canine OS. We also set out to improve NK cell therapy by generating 
NK cells resistant to TGFβ suppression. To this end, we generated a novel anti-
canine NKp46 antibody and characterized canine NK cells as CD3-/NKp46+. Canine 
NK cells have a median 3-week expansion of 20,000-fold on K562 feeder cells 
expressing membrane-bound IL-21. Canine NK cells efficiently kill OS, secrete IFNγ 
and TNFα, and express genes for NK cell receptors. Using a novel non-genetic 
approach, we generated human NK with reduced sensitivity to TGFβ- Resistant NK 
(ReNK). ReNK retain high cytolytic activity and produce remarkably more IL-6, IFNγ, 
vi 
 
and TNFα plus and minus TGFβ treatment compared to Standard NK cells. We 
characterized the TGFβ pathway in ReNK and found a near complete loss in 
SMAD3 protein and decreased TGFBR3 expression. ReNK also have enhanced 
STAT3 activation. In summary, we characterized canine NK cells, establishing the 
necessary tools to test NK cell therapy in canines to inform the use of NK cells in 
both human and canine OS. We also generated NK cells with enhanced anti-tumor 
activity that represent a promising therapeutic option for tumors with high TGFβ 
production such as OS and brain tumors.   
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Chapter 1: Background 
1.1 Osteosarcoma 
Osteosarcoma (OS) is the most common primary bone cancer in children and 
adolescents, with a peak incidence just after the pubertal growth spurt. The standard 
of care is surgical resection and MAP chemotherapy (cisplatin, doxorubicin, 
methotrexate). Metastatic OS has a less than 30% 5-year survival rate. In addition, 
OS survival has not improved in over 30 years. Survivors of OS face life-long 
handicaps and limitations due to limb-salvage surgeries and amputations as well as 
long-term toxicities of chemotherapy (1-3).  
Development of new therapies for OS has been hindered by the genetic 
heterogeneity and interpatient variability of OS. This has confounded the discovery 
of OS tumor-driving genes and the development of targeted therapies. 
Retinoblastoma-associated protein 1 (RB1) and p53 mutations, such as in 
Retinoblastoma and Li-Fraumeni syndrome, are associated with an increased 
frequency of OS development. Mutations are also frequently found within the mTOR 
and NOTCH pathways, and Erb family. Recent studies have also identified 
dysregulations in microRNA (miRNA) and long non-coding RNA expression, 
particularly in those that regulate cell cycle progression (3, 4).  
Due to the lack of effective treatments for metastatic OS, there have been 
several new clinical trials testing new therapies. Recently, the European and 
American Osteosarcoma Study Group (EURAMOS) trial closed. In the EURAMOS 
trial, IFNαβ or ifosfamide and etoposide were added to the standard MAP 
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chemotherapy regimen. However, this new treatment regime did not improve 
outcomes for OS, and instead increased treatment toxicity (5, 6). Another trial used 
metronomic chemotherapy, which involves the frequent administration of low-dose 
chemotherapy. Metronomic chemotherapy was chosen with the goal of inhibiting 
angiogenesis and stimulating an immune response. Unfortunately, this trial also 
failed to improve survival for both human OS patients (7, 8). A new approach 
towards OS treatment involves the use of natural killer (NK) cells, cells of the innate 
immune system that are highly effective at killing malignant cells, including 
chemotherapy resistant OS; yet, there is very little data on their clinical efficacy (9). 
1.2 NK Cell Background 
This chapter is based upon Foltz, J.A., J. S. Miller, D. A. Lee. In press. NK 
Cell Based Immunotherapy. In Immunotherapy in Translational Cancer Research. 
John Wiley & Sons, Inc., Hoboken, NJ, USA. (ISBN: 9781118123225) with 
permission from Claire Bonnett, Publisher at John Wiley & Sons. 
NK cells were originally described in the 1970’s as null lymphocytes with 
natural cytotoxicity against mouse tumor cell lines distinct from T-cell killing, which is 
antigen-specific and Class I major histocompatibility complex (Class I MHC) 
dependent (10-14). Decades later, we now understand that NK cells differ from T-
cells by their expression of a repertoire of germline-encoded activating and inhibitory 
receptors that bind to conserved cell-surface protein ligands (Table 1), in contrast 
with the recombined receptors of T cells that bind to peptide antigens. The activating 
receptors identify elements of stress or danger, and are balanced by inhibitory 
receptors that recognize self. Through the balance of these activating and inhibitory 
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receptors, NK cells determine which cells to kill, such that the engagement of more 
activating than inhibitory receptors results in signal activation and subsequent 
effector responses- cytotoxicity and cytokine release.  
Unlike T-cells in which recognition of peptide and Class I MHC leads to 
activation, NK cells are generally inhibited by recognition of Class I MHC. Thus, 
activation is more likely to occur against cells that lack MHC expression, termed 
“missing self” (14, 15). NK cells are highly important in the surveillance and 
destruction of virus and parasite-infected cells and tumor cells (16) because they 
over-express activating ligands and downregulate MHC.  
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Table 1. Major Human NK cell receptors for which corresponding ligands are 
known 
Receptor    Ligand  
Activating Receptors 
FcRIII (CD16)   IgG1/IgG3 antibody 
NKp30 (CD337)   BAG6, B7-H6 
NKp44 (CD336)   PCNA 
NKp46 (CD335)   viral hemagglutinin 
NKp80    AICL 
NKG2D (CD314)   MICA, MICB, ULBP1-6 
NKG2C/E (CD159c, e)  HLA-E 
DNAM-1 (CD226)   PVR, Nectin-1 
2B4 (CD244)    SLAMF2 (CD48) 
 
Inhibitory Receptors 
KIR2DL1 (CD158a)   HLA-C group 2 
KIR2DL2/DL3 (CD158b, b2) HLA-C group 1 
KIR3DL1/DL2 (CD158e, k)  HLA-Bw4 and some HLA-A 
NKG2A (CD159a)   HLA-E 
1.3 NK Cell Receptors 
Phenotypically, NK cells in humans are defined by their lack of CD3 (e.g., 
lacking a T-cell receptor), and expression of CD56, CD16, or NKp46. NKp46 is part 
of a distinct family of activating receptors expressed by NK cells - the natural 
cytotoxicity receptors (NCRs) - which are implicated in NK cell mediated killing of 
tumors and also include NKp30 and NKp44. Higher expression levels of the NCRs 
are correlated with increased tumor killing (17, 18) and is often reduced in cancer 
patients compared to healthy individuals (19-22), thus predicting survival from some 
cancers (23). NKp46 is unique among the NK cell receptors because it is nearly 
exclusively expressed on NK cells (24-26). On the contrary, NKp44 expression is 
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limited to interleukin-2 (IL-2) activated NK cells and NKp30 is expressed only on a 
subset of NK cells. Despite the importance of the NCRs in NK cell killing of tumors, 
the majority of their ligands on tumors remain unknown (15, 18). 
The primary activating receptors on NK cells that mediate recognition of 
cancer cells include NKG2D, DNAM-1, 2B4, NKp80, and CD16 (15). These 
activating receptors can act in synergy when the ligands for more than one activating 
receptor are present on the target cells (27). 
NKG2D is a homodimeric lectin receptor that recognizes a variety of stress-
induced ligands present on cancer cells. The ligands for NKG2D include MHC class 
I chain-related protein (MIC) A and B and UL16 binding protein 1–6 (28), which are 
expressed on virtually all tumor types including brain tumors, carcinomas, sarcomas, 
neuroectodermal cancers, lymphomas, and leukemias (29-35). 2B4 recognizes 
stress ligands of the SLAM family, and DNAM-1 recognizes the viral receptors PVR 
and Nectin (15). 
CD16 is the low-affinity immunoglobulin receptor (FcRIII) responsible for 
mediating antibody dependent cellular cytotoxicity (ADCC) in NK cells. ADCC 
augments NK cell killing through the binding of IgG antibodies to CD16 and a tumor 
cell ligand (15, 36). Two examples of exploiting ADCC for increasing NK cell killing 
are rituximab (anti-CD20) and dinutuximab (anti-GD2) antibodies. NK cell-dependent 
ADCC is a key mechanism of action for both rituximab and dinutuximab, and pre-
clinical data support their combination with NK cell infusions. Rituximab is a chimeric 
monoclonal antibody (mAb) against CD20 expressed on B-cells. NK cell mediated 
ADCC is a major mechanism of action for rituximab therapeutic efficacy (37-39), and 
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loss of ADCC through decreased CD16 affinity for IgG is a recognized mechanism of 
loss of clinical benefit (40). GD2 is a disialoganglioside that is expressed on many 
solid tumor types. In vitro and in vivo mouse studies with both primary NK cells and 
activated, expanded NK cells demonstrate that the addition of anti-GD2 mAb 
improves NK cell cytotoxicity against neuroblastoma and survival of mice with 
neuroblastoma xenografts (32, 41). Efficacy of anti-GD2 mAb in clinical trials is 
associated with NK cell function (42, 43). 
NK cells possess several inhibitory receptors, which are used to distinguish 
between healthy cells and malignant or infected cells. The inhibitory receptors are 
largely made up of a family of receptors called killer immunoglobulin receptors (KIR) 
and NKG2A/CD94 receptor. However, some KIRs and the related NKG2C receptor 
are activating. The ligands for inhibitory KIR are classical Class I MHC (mostly 
human leukocyte antigen (HLA)-B, C) and are grouped into specific receptor-ligand 
interaction groups (KIR2DL1 for HLA- C1, KIR2DL2/3 for HLA-C2, and KIR3DL1 for 
Bw4). While KIR2DS1 binds HLA-C2, resolving the ligands for other activating KIR 
ligands continues to evolve. The ligand for NKG2A and NKG2C is the non-classical 
HLA-E. Inhibitory receptor engagement results in an inhibitory signal indicating that 
the target cell is healthy self. Many cancers downregulate HLA expression making 
them more susceptible to NK-mediated killing (44). Through HLA typing, adoptive 
cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) can 
exploit the presence or absence of specific KIR-ligand groups - mimicking missing-
self - to evade inhibition and improve outcome. Termed KIR mismatch, this requires 
identification of a donor who has an inhibitory KIR ligand (HLA group) that is not 
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expressed in the recipient. This results in the donor’s NK cells having less potential 
for inhibition in the recipient, and therefore increased killing of the recipient’s cancer 
cells (45, 46). 
The 15 KIR genes and 2 KIR pseudogenes can be inherited in many possible 
variations of gene content, and these are broadly grouped into KIR genotypes A and 
B, where type B individuals possess a greater number of activating KIRs. KIR type B 
is significantly associated with better clinical outcomes that will be discussed in more 
detail later in this chapter (15, 27, 36).   
 NK cells have several mechanisms by which they can kill tumor cells. These 
include granzyme B and perforin, Fas, and tumor necrosis factor-related apoptosis 
inducing ligand- mediated killing (TRAIL). In addition, NK cells have indirect anti-
tumor effects by stimulating other cells of the immune system through the release of 
pro-inflammatory cytokines, most notably interferon gamma (IFNγ) and tumor 
necrosis factor-alpha (TNFα) (16). These methods of killing have varying importance 
dependent on the tumor cell, with some tumors being resistant to one or more 
methods of killing (16, 47-51). Immune-modulating drugs such as bortezomib and 
lenalidomide can overcome this resistance and sensitize cancer cells to NK cell 
killing in pre-clinical models, and are currently being tested in clinical trials. 
1.4 Clinical Evidence for NK Cell Impact on Cancer Outcomes 
 Low NK cell numbers and deficient NK function are correlated with cancer risk 
(52, 53) and can be highly predictive of treatment outcome (53-56). In patients with 
acute myeloid leukemia (AML), NK cells have reduced NKp30 and NKp46 
expression compared to healthy individuals, and this reduced expression correlates 
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with decreased cytotoxicity against leukemia cells. Expression of NKp46 and NKp30 
is significantly increased in patients with AML upon achieving complete remission 
(CR) as compared to expression at the time of diagnosis, and increased expression 
correlated with overall survival (19, 20, 23). In addition to phenotypic differences, NK 
cells from leukemia patients are deficient in their cytokine production, and cytokine 
production and cytolytic activity against autologous leukemic blasts are positively 
associated with relapse-free survival and CR, respectively. NK cell cytotoxicity 
against autologous leukemia cells above 12% significantly correlated with a 100% 
disease-free survival of greater than 8 years. Thus, NK cells play a significant role in 
the host anti-leukemic response (57, 58).   
 Similarly, in solid tumors, NK cell function and phenotype are implicated in 
disease prognosis and progression. In osteosarcoma, increased lymphocyte 
recovery following chemotherapy is significantly associated with improved 5-year 
overall survival (24). In both breast and prostate cancer, the number of activated NK 
cells in peripheral blood correlated with improved survival (56, 59). In patients with 
melanoma, NK cells have lower expression of NK activating receptors and reduced 
NK functionality (cytotoxicity, cytokine secretion, and proliferation) compared to 
healthy controls. This dysfunction may be an immune-escape mechanism induced 
by cell-to-cell contact, as co-culture of NK cells with melanoma results in decreased 
activating receptor expression and decreased cytotoxicity (21, 22, 60). These 
dysfunctional changes are also seen in lung cancer, and can be reversed in vitro 
with TIM-3 blockade (61, 62).   
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1.4.1 Adoptive Transfer of NK Cells 
The combination of in vitro findings of cancer sensitivity to NK cell lysis, in vivo 
evidence of reduced NK cell number and function in patients with cancer, and high 
sensitivity of NK cells to chemotherapy and radiation that further decreases NK cell 
numbers in these patients, results in NK cell adoptive transfer having the potential to 
restore NK cell function and improve cancer treatment. To this end, several methods 
have been developed for producing an NK cell product for infusion. A 
lymphodepleting pre-conditioning regimen is typically included with the goal of 
making physiological “space” in the recipient, which in turn promotes NK cell 
expansion in vivo through increased availability of the homeostatic cytokine, IL-15 
(63). After the pre-conditioning regimen and NK cell infusion, IL-2 (aldesleukin) (or 
more recently, IL-15) administration can be given to further promote NK cell 
persistence and expansion in vivo.  
The majority of completed studies have used primary NK cells derived from 
peripheral blood apheresis of a normal donor followed by depletion of T cells (CD3 
depletion) to prevent GvHD, and in some cases B-cells (CD19 depletion) to prevent 
passenger lymphocyte syndrome or reactivation of Epstein Barr virus (63, 64). Other 
studies seeking to infuse a NK cell product of increased purity have utilized CD3 
depletion followed by CD56-positive selection to isolate NK cells. However, this 
method reported reduced NK cell yield, which may be an issue especially in adult 
patients. After selection or depletion, the NK cell product can be administered 
immediately, activated with cytokines, or expanded ex vivo for generating greater NK 
cell doses. 
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1.4.2 Expanded NK cells. 
Since collection of primary NK cells by steady-state apheresis is not able to 
achieve large NK cell doses, ex vivo expansion of NK cells has been explored to 
enable higher NK cell numbers per infusion and for repeated NK infusions. 
Expanded NK cells are also more activated than primary NK cells against tumor 
targets (65, 66). In addition, NK cells in patients with cancer are often functionally 
impaired and infusions of autologous NK cells in early trials were safe but showed 
no clear benefit. Ex vivo activated and expanded NK cells may correct that 
dysfunction. 
There have been several methods developed for ex vivo expansion of NK 
cells. Approaches have generally centered on either cytokine-induced proliferation or 
feeder cell lines engineered to stimulate NK cell growth. For cytokine-induced 
proliferation, IL-2 in combination with IL-12, IL-15, or IL-18 are usually used. 
Cytokines have been effective at generating memory-like NK cells with enhanced 
function; however, proliferation with cytokines alone is limited by a low yield of NK 
cells (67).  
On the other hand, feeder cell lines such as the K562 leukemia cell line, 
which is highly sensitive to NK cell killing, have been much more successful at 
generating large-fold expansion of NK cells (65, 66, 68). This K562 cell line was 
modified to express 41BBL and either membrane-bound IL-15 (K562 mbIL-15) or IL-
21 (K562 mbIL-21). The Lee Lab compared NK expansion on K562 mbIL-15 to K562 
mbIL-21 and found that K562 mbIL-21 promotes increased proliferation (median: 31, 
747-fold vs. 325-fold in 3 weeks) and increased secretion of IFNγ and TNFα 
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compared to mbIL-15, while maintaining potent anti-tumor cytotoxicity (66). EBV-
transformed cells have also been used as feeder cells for stimulating NK cell 
proliferation (68, 69). An EBV-transformed cell line with IL-2 plus IL-21 generated NK 
expansion of 1011 in 6 weeks; however, the authors noted that the expanded NK 
cells lost their anti-tumor cytotoxicity after injection into mice (70). Finally, NK cells 
have been expanded using irradiated PBMCs as a feeder cell with the addition of IL-
2 and OKT3 (71-73). 
1.5 NK cells in Osteosarcoma 
Despite the clinical trials underway for NK cells in other malignancies, to date 
no NK cell clinical trial specifically focused on OS has opened. Human OS patients 
have decreased numbers of circulating NK cells, suggesting that NK cell deficiencies 
may play a role in the development of OS (74). However, upon ex vivo activation 
with IL-15, patient-derived NK cells become highly cytotoxic, able to kill both 
chemotherapy-resistant allogeneic cell lines and autologous tumor biopsies (9). 
Murine models of adoptively transferred K562 mbIL-21 expanded NK cells have 
potent anti-tumor activity in murine xenograft models of metastatic OS. This anti-
tumor effect can be augmented by the addition of aerosolized IL-2 (75, 76). In 
addition, NK cells can target OS cancer stem cells (77). OS expresses GD2 and 
EGFR, and the administration of antibodies to these antigens, (dinutuximab & 
cetuximab, respectively) can augment NK cell killing of OS through ADCC (78). 
1.6 Tumor Avoidance of NK Cell Surveillance 
 Despite the in vitro and in vivo activity of NK cells, immune therapies have 
been largely ineffective at eradicating minimal residual disease in patients. This is 
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believed to be due to the immune suppressive environment of the tumor caused by 
tumor cells themselves, myeloid derived suppressor cells, T-cells, and the stroma. 
Tumors can evade NK cell surveillance through several mechanisms. These include 
release of soluble NKG2D and NKp30 ligands, which then bind to the corresponding 
receptor on the NK cell, blocking engagement of the NK cell with the tumor, and 
preventing tumor cell lysis (79, 80). In addition, L-kynurenine which is generated 
from the breakdown of tryptophan by indoleamine-2,3-dioxygenase (IDO) induces 
selective downregulation of NKp46 and NKG2D in NK cells, leading to decreased 
killing of cell lines that are killed through NKp46 and NKG2D receptor engagement 
(81). IDO derived L-kynurenine can also inhibit NK cell proliferation (82). Another 
method of immune evasion is the hypoxic tumor microenvironment. Hypoxia inhibits 
cytokine-induced upregulation of the NCRs and NKG2D, but not CD16. This 
corresponds with decreased anti-tumor activity but maintenance of ADCC (83, 84).  
Tumor-associated fibroblasts also negatively modulate NK cell anti-tumor function 
through both cell-cell contact and secretion of PGE2 (85). 
Another important method of suppression is the release of tumor growth 
factor- beta (TGFβ). TGFβ is a potent inhibitor of NK cell anti-tumor activity and is 
believed to be an underlying cause for the inability of cell-based therapies to 
eradicate minimal residual disease (86). TGFβ is released from numerous cell types 
within the tumor microenvironment including NK and T-cells themselves, tumor 
associated fibroblasts and macrophages, myeloid derived suppressor cells, tumor 
cells, and regulatory T-cells (Tregs) (87, 88). Cancer patients, particularly in brain 
and solid tumors, have elevated serum TGFβ levels that correlate with disease 
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severity (89-93). Both human and canine OS patients have elevated serum TGFβ 
levels (94, 95). TGFβ inhibits NK cell IL-2 induced proliferation and decreases 
expression of several activating receptors including NKG2D, NKp30, and CD16 (87, 
96). Through phosphorylation of SMAD3 by TGFβ, TGFβ inhibits NK cell secretion of 
IFNγ, TNFα, and chemokines (97-100). TGFβ inhibits NK cell cytotoxicity by 
impairing the release of granzymes and perforin (43, 101).  
However, TGFβ plays an important role in homeostasis of immune cell 
development and activity such as in the prevention of autoimmunity (102). TGFβ 
promotes the development of T-cells in the thymus by upregulating IL-7Rα and 
promoting the survival of Tregs (103). Tregs, in turn, support peripheral tolerance by 
suppressing inflammatory Th1 cells, CD8+ T-cells, and NK cell activity, inhibiting 
anti-self reactions (104). TGFβ decreases B cell and T-cell function and number by 
inhibiting proliferation and T-cell production of IL-2 (105-108). TGFβ also induces the 
release of other immune suppressive proteins, such as IDO in dendritic cells (109). 
However, TGFβ’s ability to suppress T-cell and dendritic cell function can be 
abrogated by ligation of CD28 or CD40, respectively, demonstrating that TGFβ’s 
effect on the immune system is context dependent (110). 
1.7 Dog Models of Cancer 
 Canines are an established spontaneous animal model for cancer. Canines 
naturally develop many cancers with high homology to human cancer including OS, 
melanoma, lymphoma, glioma, prostate, and mammary cancer. Many of these 
cancers have similar tumor driving genes. In addition, canines as household pets, 
share the same environment with humans allowing for study on the effect of 
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environmental exposures on tumor development. Of particular interest to immune-
based therapies, canines have a fully intact immune system and complete tumor 
microenvironment (111, 112). Since the lifespan of canines is much shorter than 
humans, cancer progresses at a significantly faster rate allowing for rapid testing of 
therapeutics. This can be used to assess the efficacy of new therapies and to 
prioritize the translation of promising therapies from canines to humans (111). 
 Canine models have been effective in generating pre-clinical data for several 
new therapies which had successful translation to humans. For example, canines 
were used to develop bone marrow transplant protocols for subsequent use in 
humans (113, 114). Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, was tested in 
canines with non-Hodgkin’s lymphoma before being approved for human use, where 
it has been highly effective in the treatment of lymphomas (115, 116). In OS, canines 
were used to optimize limb-sparing surgical removal of the primary OS tumor (117). 
Recently, the success seen in a pre-clinical trial in canine glioma using EGFR-mini 
cells loaded with doxorubicin facilitated the opening of a clinical trial in human 
glioblastoma (NCT02766699) (118). In breast cancer, a p62 DNA vaccine 
demonstrated efficacy in a pre-clinical trial in canines, and the recent completion of a 
Phase 1 trial in human breast cancer reported the same finding where patients 
receiving the vaccine had delayed disease progression (119, 120). 
Several immune based therapies have also recently been tested in canines. 
These include ex vivo expanded T-cells engineered to express a CD20-CAR for 
lymphoma or a HER2-CAR for OS (121-123). In human patients, T-cells expressing 
a CD19 CAR, similar to the canine counterpart of CD20, have been effective in 
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treating lymphoma (124, 125). A phase 1 clinical trial in human OS recently closed 
and demonstrated that HER2-CAR T-cells are well-tolerated, and 4/17 patients had 
stable disease following T-cell infusion (126, 127).  
Canines have also been used for retrospective evaluation of why drugs failed 
in human clinical trials. For example, iniparib which first demonstrated preliminary 
efficacy in human breast cancer trials, later did not improve survival. This culminated 
in lack of FDA approval. In response to these findings, a trial opened up in canines 
with melanoma, soft tissue sarcoma, and squamous cell carcinoma with the goal of 
better understanding why iniparib failed in humans. Similar to the findings in 
humans, iniparib did not improve survival in canine cancers despite administering 
doses significantly higher than used in human trials (up to 70 mg/kg in canine versus 
5.6 mg/kg), and it was found that iniparib did not have substantial infiltration into 
tumors. Thus, the canine model can also be used to provide answers to why 
treatments fail in human clinical trials (128, 129).  
1.7.1 Canine Osteosarcoma as a Pre-clinical Model for Human Osteosarcoma 
Canine OS occurs with much higher frequency than human OS facilitating the 
pre-clinical testing of new therapies in this model. Of the over 1 million dogs 
diagnosed with cancer every year, over 8,000 are diagnosed with OS. Canine OS 
has a similar standard of care as human OS, but has extremely poor prognosis with 
only a 50% 1-year survival rate (111, 130).  
At the genetic level, human and canine OS share all the same mutations and 
cellular signaling, highlighting the usefulness of testing novel therapies in canines 
that will provide benefit to both species (112). Canines with OS also develop 
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pulmonary metastasis. The most recent therapy to improve OS survival, Liposome- 
muramyl tripeptide phosphatidylethanolamine (L-MTP-PE; mifamurtide) was first 
tested in canine OS where it improved survival (131).  Following this study, a large 
phase III study was conducted with L-MTP-PE in conjunction with chemotherapy. L-
MTP-PE improved event-free and overall survival of human OS and is now approved 
for treatment for OS in Europe (132, 133).  
1.7.2 Canine NK Cells 
 Despite the promising in vitro and in vivo murine data for NK cells in OS, 
much less is known about canine NK cells in OS. In addition, very little is known 
about the phenotype or function of canine NK cells entirely. This has largely been 
attributed to a lack of available reagents for identifying canine NK cells. Identification 
of canine NK cells has instead relied upon either negative selection using antibodies 
specific to other immune lineage markers or identifying NK cells by their functional 
capacity to kill canine thyroid adenocarcinoma (CTAC) without prior sensitization.  
However, the use of these methods of identification of canine NK cells has led 
to conflicting results as to what constitutes NK cells in canines. For example, T-cell 
receptor (TCR) positive, TCR-, and CD3+/TCR- cells can kill the CTAC cell line. In 
addition, these TCR+ cells have a NK-like genotype including NK cell receptors such 
as NKG2D, NKp46, and CD16. Further adding to the confusion, these experiments 
have been done on mixed cell populations including both TCR+ and TCR- cells. Both 
CD3+ and CD3- NK-like cells have expanded on K562 cells transduced to express 
human 41BBL and membrane-bound IL-15 (134-139). In order to further 
17 
 
comparative NK cell biology and to test NK cell therapy in spontaneous canine OS, 
there is a great need to clarify the phenotype of canine NK cells. 
Specific Aims. 
 The goal of this dissertation was to improve NK cell therapy for OS, with the 
ultimate goal of providing the necessary tools to improve OS survival. To accomplish 
this goal, this project aimed to characterize NK cells in canines, which 
spontaneously get OS with over 8,000 new cases per year; yet, very little is known 
about the phenotype of canine NK cells. Second, to improve expansion of canine NK 
cells for adoptive transfer of NK cells in canine OS. Finally, to develop NK cells 
resistant to suppression by TGFβ through non-genetic education, ultimately having 
increased anti-tumor activity.  
Specific Aim 1: To develop and validate a standard approach to 
characterizing canine NK cell phenotype and function. In order to study NK cells in 
canine OS, characterization of canine NK cell phenotype and function is needed, 
which has thus far been done using mixed cell populations since no antibody to 
positively select for canine NK cells has been available. We hypothesized that 
canine NK cells would be identified by their expression of NKp46, the putative 
species-wide marker of NK cells, and would kill tumor targets without prior 
sensitization. Using our novel anti-canine NKp46 antibody, we characterized the 
phenotype of CD3-/NKp46+ cells by flow cytometry and PCR. We assessed the 
function of pure, sorted CD3-/NKp46+ cells by comparing to donor-matched T-cells to 
determine if CD3-/NKp46+ cells can kill without prior sensitization, and then 
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determined the cytotoxicity of CD3-/NKp46+ cells against primary and metastatic OS, 
melanoma, and thyroid adenocarcinoma canine cell lines. We determined the 
cytokine profile of CD3-/NKp46+ cells using Luminex. Finally, we identified a Lineage 
negative, NKp46- cell population (Null cells) with phenotypic and functional similarity 
to canine NK cells (CD3-/NKp46+), and compared this subset to human NKp46+ and 
NKp46- NK cells. 
Specific Aim 2: To improve NK cell expansion from healthy and OS-bearing 
canines for use in comparative oncology models. In order to test NK cell therapy in 
canines, the development of a NK cell expansion platform capable of generating 
clinically relevant numbers of NK cells was necessary. Due to the potent anti-tumor 
activity of mbIL-21 expanded human NK cells, we desired to translate this NK cell 
expansion method from humans to canines. We hypothesized that canine NK cells 
would have robust proliferation on K562 mbIL-21 feeder cells. To this end, we 
optimized expansion of canine NK cells on mbIL-21 for both healthy and OS-bearing 
canines. 
Specific Aim 3: To assess the ability of NK cells expanded in TGFβ to 
overcome TGFβ mediated suppression of NK cell Anti-tumor Activity. Both human 
and canine OS patients have elevated levels of TGFβ, which potently suppresses 
NK cell killing. Although TGFβ pathway inhibitors and dominant-negative receptors 
have demonstrated some improvement in immune therapy effectiveness, these 
methods have potential for off-target side effects. We hypothesized that expansion 
of NK cells in the presence of TGFβ would select for NK cells with reduced 
sensitivity to TGFβ suppression. To this end, we expanded human NK cells with 
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mbIL-21 feeder cells and TGFβ and compared their anti-tumor function to NK cells 
expanded without TGFβ by CD107a expression, cytotoxicity assays, and cytokine 
secretion. We also measured their cell surface and intracellular phenotype using 
flow cytometry, qPCR, and western blots. 
Chapter 2: Identification, Characterization, and Expansion of Canine NK Cells 
2.1 Background 
This chapter is based upon Foltz, J. A., S. S. Somanchi, Y. Yang, A. Aquino-
Lopez, E. E. Bishop, and D. A. Lee. 2016. NCR1 Expression Identifies Canine 
Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells. 
Frontiers in Immunology 7. with permission from NK and Innate Lymphoid Cell 
Biology- Frontiers in Immunology under the terms of the CC BY license.   
Canines are a large animal model with spontaneous development of many 
cancers, including osteosarcoma, leukemia, lymphoma, glioblastoma, prostate 
cancer, and mammary cancer. Canines provide an outbred, immune competent 
disease model with genetic heterogeneity and a shared environment with humans 
(111, 130, 140, 141). Testing of novel therapies in the canine model has educated 
the protocols for bone marrow transplants in humans, and more recently has been 
used for the testing of immune therapies such as adoptive transfer of T-cells, HER2-
Listeria vaccine, and Liposomal-muramyl tripeptide (L-MTP-PE; mifamurtide) (113, 
114, 123, 131, 142-145). 
Despite the advantages of the canine model, NK cells are less well-
characterized in canines than in mice and humans. The sequencing of the canine 
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genome in the early 2000s revealed that like humans, canines have all of the natural 
cytotoxicity receptors along with NKp80 in their genome.The primary inhibitory 
receptors that mediate licensing of NK cells are the Ly49 and KIR families of 
receptors, both of which recognize self through binding to MHC Class I. Mice have 
16 Ly49 genes but only 2 KIR, whereas humans have 16 KIR genes but only a 
pseudogene of the Ly49 family (146). The sequenced canine genomes have no KIR 
and only one Ly49 gene, which has a predicted ITIM sequence suggesting that it 
functions as an inhibitory receptor (146-148); however, there are some reports of 
canines having KIR sequences but the data supporting this claim is not publicly 
available (148). 
The identification of NK cells in canines has been met with seemingly 
conflicting results with some studies reporting CD3- cell populations with NK cell 
properties while others report CD3+ cell populations with NK cell properties (134, 
136, 138, 139). Recently, Grondahl-Rosado et al. provided more clarity on the 
phenotype of canine NK cells using a cross-reacting anti-bovine antibody to NCR1 
(NKp46), the putative species-wide marker of NK cells in mammals (26, 149-155). 
Using this antibody, they identified a CD3-/NKp46+ cell population in most canines 
that were also positive for Granzyme B. Further, they confirmed that NKp46 is an 
activating receptor in canine. They also proposed that a CD3-/NKp46-/Granzyme B+ 
cell subset may be a subset of canine NK cells (155, 156). However, this anti-bovine 
NKp46 antibody is reported by the authors to not be suitable for sorting of CD3-
/NKp46+ cells, limiting the ability to further characterize the receptor expression and 
function of CD3-/NKp46+ cells and this NKp46- cell population (155, 156). 
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Additionally, expansion of canine NK-like cells, while more successful than ex vivo 
expansion of mouse NK cells, has been significantly less than reported in humans 
with expansions reported of up to 233-fold on average in 2-3 weeks (134-139, 157).   
We sought to further characterize canine NK cells for use in osteosarcoma, 
where survival for metastatic human OS patients has largely remained stagnant at 
only 30% 5-year survival rate for the last 30 years (1, 2, 5, 6). Canine OS is highly 
prevalent, with over 8,000 new diagnoses per year, and an average survival rate of 
only 1 year, allowing for the rapid testing of new therapeutics. While mouse models 
have provided important discoveries in OS pathogenesis and treatment, the 
spontaneous canine model of OS has been well-characterized and is used as an 
additional important animal model of OS (111, 112, 130, 158).  
To this end, the goal was to develop and validate a standard approach 
towards characterizing canine NK cells and to improve ex vivo expansion of canine 
NK cells. Since NKp46 has identified NK cells in all species studied to date and has 
been proposed as the species-wide marker of NK cells due to its’ conservation 
across species which is unlike CD56, we hypothesized that NK cells in canine could 
be identified by their expression of NKp46. Extending our findings in human NK cells 
of increased NK cell proliferation with IL-21 expressing K562, we also hypothesized 
that expansion of canine NK cells would be improved compared to the literature with 
K562 mbIL-21 feeder cells.  
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2.2 Results 
2.2.1 Construction of an Anti-Canine NKp46 Antibody 
Hybridomas obtained by immunization with L-cells expressing the NKp46 
fusion protein (NKp46:L-cells) were screened via ELISA (Appendix A) and flow 
cytometry against NKp46:L-cells and Empty Vector:L-cells. Clone 48A had strong 
staining on NKp46:L-cells and no non-specific staining on Empty Vector:L-cells. 
Clone 48A was identified as a mouse IgG2a isotype and was selected for all future 
experiments (Figure 1). Clone 48A did not identify NKp46 by western blot or 
immunoprecipitation (data not shown). 
 
 
 
2.2.2 NKp46 Expression on Canine Peripheral Blood Mononuclear Cells 
Next, we identified CD3−/NKp46+ cells in lymphocytes as largely negative for 
expression of CD4 (median = 0%, IQR = 0, 1.0, n = 7), with low expression of CD5 
(median = 10.6%, IQR = 6.4, 25, n = 7) and CD8 (median = 9.3%, IQR = 4.4, 16.0, n 
= 10). NKp46 was not coexpressed with macrophage (CD14, data not shown) or B-
cell lineage markers (CD21, Figure 2). On average, 2.3% (median = 1.2%, IQR = 
Figure 1. Screening of a Novel Anti-Canine NKp46 
Antibody. Clone 48A is specific for L-cells expressing 
NKp46 (open histograms: secondary antibody only, gray 
filled: vector only, black filled: NKp46:L-cells). Mouse 
immunization and screening of hybridomas against L-cells 
was done by MD Anderson Monoclonal Antibody Core. 
Screening of hybridomas against canine cells was done by 
Jennifer Foltz. 
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0.6, 3.7, n = 12) of lymphocytes from healthy canines were CD3−/NKp46+, consistent 
with an NK cell expression pattern (Figure 2). NKp46 was also expressed on a 
subset of CD3+/TCR+ cells. 
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2.2.3 Ex Vivo Expansion of Canine CD3−/NKp46+ Cells 
Next, we expanded canine CD3−/NKp46+ cells from whole PBMC using K562 
Clone9.mbIL-21 feeder cells in a 21-day culture, since we previously demonstrated 
significantly improved expansion of human NK cells with K562 Clone9.mbIL-21 
feeder cells compared to K562 mbIL-15 feeder cells (36). The percentage of 
CD3−/NKp46+ cells in the culture was significantly increased at the end of expansion 
when using canine IL-2 (rcIL-2) compared to human IL-2 (p = 0.03, Human IL-2: 
median = 58.02, IQR = 10.05, 65.16; Canine IL-2: median = 72.9, IQR = 32.25, 
84.35; n = 6) (Figure 3). There was significantly increased yield of CD3−/NKp46+ 
cells (p = 0.03) at the end of expansion with rcIL-2 (Figure 3) (Human IL-2: median 
= 7.07 × 107, IQR = 2.9 × 107, 1.67 × 108; canine IL-2: median = 1.71 × 108, IQR = 
9.58 × 107, 5.65 × 108, n = 6). For all future expansions reported, rcIL-2 was used. 
Figure 2. Expression of NKp46 on canine PBMC using a novel anti-canine 
NKp46 antibody. NKp46 is expressed on CD3− and CD3+ lymphocytes. 
CD3−/NKp46+ cells make up on average 2.3% of lymphocytes. Shown is 
median ± IQR (n = 12). Representative flow plot is shown. CD3−/NKp46+ cells are 
largely negative for CD4 (median = 0%), and a subset express CD8α 
(median = 9.3%), and CD5low/− (median = 10.6%) (Solid line: negative control, 
Black filled: CD3−/NKp46+, Dotted line: CD5 expression on total lymphocytes 
showing two populations of CD5+ cells). Shown is median ± IQR for CD4 (n = 7), 
CD5 (n = 7), and CD8 (n = 10). NKp46 is not expressed on CD21+ B-cells. 
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When PBMC was cultured for 21 days on K562 Clone9.mbIL21 with rcIL-2, 
CD3−/NKp46+ cells made up a median 62.31% (IQR = 45.7, 83.7, n = 16) and CD3+ 
T cells comprised a minor portion (median = 23.85%, IQR = 6.9%, 47.7%, n = 16) of 
the total expanded cell product (Figure 4), with the exception of two outliers. The 
phenotype of the CD3−/NKp46+ cells significantly changed during expansion, with 
CD5 decreasing (p = 0.037, Median = day 0: 10.6, IQR = 6.42, 25; day 21: 0.35, IQR 
= 0.1, 1.02) and CD8α increasing (p = 0.005, Median = day 0: 9.33, IQR = 4.35, 
16.03; day 21: 35, IQR = 22.7, 48.1) (Figure 4). 
 
 
Figure 3. Expansion of CD3−/NKp46+ cells on K562 mbIL-21 feeder cells 
with human versus canine IL-2. Canine CD3−/NKp46+ cells expanded on K562 
Clone 9.mbIL-21 feeder cells for 3 weeks with canine IL-2 have significantly 
increased purity and yield of CD3−/NKp46+ cells compared to expansion with 
human IL-2 (n = 6) Canine donors are depicted by connecting lines. 
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To further characterize the expanded CD3−/NKp46+ cells, for which antibodies 
to other NK cell receptors are not available, semi-quantitative RT-PCR was 
performed on sorted CD3−/NKp46+ cells from 5 different donors for several known 
Figure 4. Phenotype of Canine CD3-/NKp46+ cells Expanded on K562mbIL-21 
feeder cells. CD3−/NKp46+ cells expand on K562mbIL-21 feeder cells to make up 
on average 60.2% of total cells, with contaminating T-cells on average 31.8% (n 
= 16, median ± IQR shown). Expanded CD3−/NKp46+ cells are CD4− 
(median = 0.08%) and have significantly decreased CD5 expression 
(median = 0.4%, p = 0.037) (open histogram = negative control, black 
filled = CD3−/NKp46+) and increased CD8 (median = 35%, p = 0.005, n = 7; 
median ± IQR shown). 
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human or mouse NK cell-associated genes for which canines are predicted to have 
homologous genes. Expanded NK cells from all donors expressed mRNA for 
NKp46, NKp30, NKp44, NKp80, NKG2D, DNAM-1, CD16, Ly49, Granzyme B, and 
Perforin, confirming that canine CD3−/NKp46+ cells express typical NK cell-
associated genes (Figure 5). 
 
 
 
 
Expansion of CD3−/NKp46+ cells with K562 Clone9.mbIL-21 feeder cells for 
21 days yielded a median 1.7 × 108 CD3−/NKp46+ cells (mean = 4.5 × 108, IQR = 1.1 
× 108, 7.5 × 108) from a starting product of 7,000 (median) CD3−/NKp46+ cells (IQR 
= 2,375, 25,750, n = 10) (Figure 6) representing a median 20,283-fold expansion 
(mean = 89,151, IQR = 5,655, 108,749, n = 10; 2 week median fold-expansion: 
4,622, 2 week mean fold expansion: 12,319 mean, n = 10). Expansion was 
Figure 5. Gene Expression of CD3-/NKp46+ cells. CD3−/NKp46+ cells express 
mRNA for NKp46, NKp30, Perforin, Granzyme B, NKG2D, DNAM-1, NKp80, 
NKp44, Ly49, and CD16 (n = 5, all PCR reactions were conducted 
concurrently). 
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successful in 9/10 donors tested. The one donor where expansion was not 
successful had the lowest percentage of CD3−/NKp46+ in PBMC of all donors tested.  
 
 
 
 
 
Since expansion of CD3−/NKp46+ cells from whole PBMC resulted in donor-
dependent T-cell contamination that would be detrimental in an allogeneic setting, 
we depleted T-cells from PBMC using FACS-sorting, leaving B-cells and 
macrophages/monocytes in the culture. We previously observed with human NK cell 
expansion that these cells provide support for NK cell expansion without hindering 
cell purity (36). Using this approach, the purity of CD3−/NKp46+ cells significantly 
increased (median = 96.5 versus 40.7%; p = 0.01) and fold expansion was not 
affected with 2/3 donors demonstrating increased fold expansion with T-cell 
depletion (Figure 7). 
Figure 6. Expansion of Canine CD3-/NKp46+ cells on K562mbIL-21 feeder 
cells. On average, 4.5 × 108 (median = 1.7e8) CD3−/NKp46+ cells are produced 
at the end of 3 weeks from an average 17,774 CD3−/NKp46+ (median = 7,000) 
cells at day 0 (shown is median ± IQR) representing a median 20,283-fold 
expansion. 
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  Figure 7. CD3 Depletion Improves NK Cell Purity. Depletion of T-cells at day 0 
significantly increases the purity of CD3−/NKp46+ cells at day 21 (95.8 versus 
40.6%) and does not hinder fold expansion (157,281 versus 64,686, n = 3). 
Connecting lines identify matched donor. 
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2.2.4 Function of CD3−/NKp46+ Cells 
To determine whether CD3−/NKp46+ cells are able to kill spontaneously, a 
hallmark of NK cell function, cytotoxicity of expanded pure CD3−/NKp46+ cells and 
CD3+ T-cells from the same donor was assessed against the canine osteosarcoma 
cell line, Gray. CD3−/NKp46+ cells had significantly increased cytotoxicity than T-
cells [p = 0.009, Median: NK = 30.92, IQR = 19.1, 48.4; T-cells = 5.36, IQR = 2.3, 
13.06; 2.5 Effector:Target (E:T) Ratio], and this increase was consistent across three 
different E:T ratios (Figure 8).  
 
 
 
Next, we assessed the cytotoxicity of CD3−/NKp46+ cells against 3 
osteosarcoma cell lines and one thyroid adenocarcinoma line. CD3−/NKp46+ cells 
displayed titratable, donor-dependent cytotoxicity against all of the 4 lines including 
metastatic (Gray) osteosarcoma and the thyroid adenocarcinoma line, CTAC. 
(Figure 9). Thus, CD3−/NKp46+ cells appear to possess NK cell function and 
Figure 8. Canine CD3-/NKp46+ cells kill without Prior Sensitization. Sorted 
CD3−/NKp46+ cells have increased cytotoxicity against the canine osteosarcoma 
(Gray) cell line when compared to CD3+ T-cells (n = 6). 
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CD3−/NKp46+ will be used interchangeably with NK cells for the rest of the 
dissertation. To determine cytokine secretion capabilities of canine NK cells, NK 
cells were compared to CD3+ T-cells from the same donor after 6 hours coculture 
with K562 Clone 9.mbIL-21 feeder cells, since 6 hour co-culture is optimal for human 
NK cell cytokine secretion against K562 targets (159). Canine NK cells secreted 
GM-CSF, IFNγ, KC-like, IL-8, IL-10, and TNFα in response to K562 mbIL-21 
stimulation. Cytokine secretion was similar to T-cells for all (Figure 9). There was no 
detectable secretion of IL-2, IL-6, IL-7, IL-15, IL-18, IP-10, or MCP-1 at baseline or 
after coculture with K562 Clone 9.mbIL-21 cells in either CD3−/NKp46+ cells or T-
cells (not shown). 
 
A) 
B) 
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2.2.5 NKp46 Identifies Distinct Subsets of NK Cells 
We observed that NKp46 was not expressed on all lineage negative 
(CD3−/CD21−/CD14−) cells in both PBMC (Figure 10a) and expanded cells (Figure 
4), with donor-dependent variation in the percent of null cells 
(CD3−/CD21−/CD14−/NKp46−) observed. Null cells made up 0–13.52% of 
lymphocytes at day 0 (median = 4.5%, IQR = 2.54, 6.40), and 0–18.4% of the final 
expanded cell product (median = 5.0%, IQR = 0, 11.8) (Figure 10a).  
Next, we determined the phenotype of these Null cells. Null cells had similar 
expression of CD4 (PBMC: median = 4.7%, IQR = 2.01, 14.2, n = 8; day 21: 0.6%, 
IQR = 0.03, 1.91, n = 9) and CD5 (PBMC: median = 4.07%, IQR = 3.72, 6.45, n = 8; 
day 21: 3.5%, IQR = 0.38, 7.89, n = 9) compared to CD3−/NKp46+ (NK) cells, but 
reduced expression of CD8 at day 0 (p = 0.02, Median = 3.1%, IQR = 0.9, 5.33, n = 
Figure 9. Canine NK Anti-Tumor Cytotoxicity and Cytokine Secretion. Canine 
A) CD3−/NKp46+ cells have titratable, donor dependent cytotoxicity against four 
different canine osteosarcoma cell lines: Gray (n = 2), OSCA8 (n = 3), and 
OSCA40 (n = 3), and the canine thyroid adenocarcinoma cell line (CTAC, n = 3) 
(mean ± SD for each donor depicted). Unique symbols identify different donors. 
B) Expanded CD3−/NKp46+ cells secrete GM-CSF, IFN-γ, KC-like, IL-8, IL-10, 
and TNF-α upon coculture with K562 Clone9.mbIL-21 feeder cells (n = 7, median 
depicted). When compared to CD3+ T-cells (n = 3) and also expanded on K562 
mbIL-21, CD3−/NKp46+ cells secrete the same cytokines at similar 
concentrations. 
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7). However, similar to NK cells, CD8 expression in the null cells was significantly 
increased at day 21 compared to day 0 (p < 0.001, day 21 = 54.6%) (Figure 10b).  
A significant negative correlation between percent of CD3−/NKp46+ cells at 
day 0 and CD3−/NKp46+ fold expansion was observed (r = −0.81, p = 0.022, not 
shown), which led us to question whether Null cells were significantly contributing to 
the yield of NK cells at day 21. When null cells were included in the fold expansion 
calculations, the mean fold expansion was 50% less than when using NKp46+ cells 
only, representing at most a two-fold over-estimation of expansion rates if all of the 
Null cells represented an NK population (Figure 10c). 
 
  
Figure 10. Phenotype of CD3−/CD21−/CD14−/NKp46− (Null) cells in K562mbIL-
21 Expanded Cells. CD3−/CD21−/CD14−/NKp46− (Null) cells are present in 
canine PBMC A) as described for expanded cells in Figure 3A. Null cells consist 
of on average 5.1% of lymphocytes in PBMC, and 5.7% of expanded cells 
(median ± IQR shown, day 0 n = 8, day 21 n = 12). B) Null cells have negligible 
expression of CD4, CD5, and CD8 in PBMC, but increase CD8 expression with 
expansion similar to CD3−/NKp46+ cells (3.1–52.4%, n = 7, median ± IQR shown. 
C) The addition of null cells to fold expansion calculation decreases mean fold 
expansion by 50% (n = 8, median ± IQR shown).   
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We questioned whether NKp46 might be inducible in these null cells as has 
been described in porcine NKp46− cells (27). To address this question, we sorted 
the expanded cells into pure NK and Null cell populations and restimulated them on 
K562 Clone 9.mbIL-21 feeder cells for five additional days. At the end of 5 days, 
NKp46 was expressed in Null cells (Null: median = 66.15, IQR = 29.69, 80.33; NK: 
93.32, IQR = 57.57, 96.7) (Figure 11a).  
Since NKp46 could be induced in formerly Null cells, we then determined if 
the Null cells express other NK cell-related genes. Since antibodies to other NK cell 
receptors are not available, we assessed the expression of several key NK cell 
receptors by qPCR. Confirming our flow cytometry data, NKp46 mRNA was 
significantly decreased in Null cells (p = 0.004). Null cells express Granzyme B (n = 
3), Perforin (n = 4), and DNAM-1 (n = 4) at similar levels compared to NK cells. 
However, NKG2D (p = 0.04) and CD16 (p = 0.009, all n = 4) were significantly 
decreased compared to NK cells (Figure 11b). 
 Figure 11. Null Cells can be induced to express NKp46, and Null cells 
express other genes for other NK cell Receptors. A) NKp46 can be induced in 
Null cells after 5 days coculture with K562 Clone 9.mbIL-21 feeder cells, while 
NKp46 expression is constant in sorted CD3−/NKp46+ cells (n = 7). B) Expanded 
Null cells express similar levels of DNAM-1, Perforin, and Granzyme B, but 
decreased expression of NKp46, NKG2D, and CD16, compared to CD3−/NKp46+ 
cells (mean ± SD shown). 
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Since Null cells are capable of expressing NKp46 along with other NK cell 
genes, we wanted to determine if Null cells have NK cell function. Expanded NK 
(CD3−/NKp46+), Null (CD3−/NKp46−), and T-cells (CD3+) were sorted from the same 
donor. Null cells had significantly decreased cytotoxicity compared to NK cells (p = 
0.008), but increased cytotoxicity compared to T-cells (p = 0.01) (Median: NK = 
27.1%, IQR = 17.3, 39.3; Null = 15.7%, IQR = 4.4, 27.5; T-cell = 3.7%, IQR = 2.07, 
6.24) (Figure 12a). Null cells had similar cytokine secretion capacity compared to 
NK cells (Figure 12b). 
A) 
B) 
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Finally, we sought to determine if human NK cells have similar subsets of 
NKp46 expressing cells. Using mass cytometry data of human CD3−/CD56+ primary 
NK cells and K562 Clone9.mbIL-21-expanded NK cells, we found several striking 
similarities between human and canine NK cells. NKp46−/CD3−/CD56+ make up 21% 
of primary NK cells and 21.7% of mbIL-21 expanded NK cells (Figure 13a). NKp46− 
NK cells are primarily found within the CD56dim NK cell subset (Figure 13c). Primary 
and expanded human NKp46− NK cells had reduced expression of NKG2D (Primary 
– CD56dim: p = 0.02; Expanded – CD56bright: p = 0.02, CD56dim: p = 0.002), and 
CD16 (Primary – CD56bright: p = 0.0035, CD56dim: p = 0.0025; Expanded – CD56bright: 
p = 0.02, CD56dim: 0.0012) (Figure 13b). In contrast to canine Null cells, NKp46− 
primary and expanded human NK cells had reduced expression of DNAM-1 (Primary 
Figure 12. Function of Null Cells. A) Expanded Null cells have decreased 
cytotoxicity against Gray and melanoma-12 [n = 9, mel-12 (in black) = 4, Gray = 6 
(in blue), individual donors designated by unique symbols, median ± IQR shown], 
B) but similar cytokine secretion (n = 3) compared to CD3−/NKp46+ cells (n = 7, 
median depicted). 
A) B) 
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– CD56dim: p = 0.01, Expanded – CD56dim: p = 0.01) and Perforin (Expanded- 
CD56bright: 0.04, CD56dim: 0.01).Next, we used Spade to determine if NKp46− NK 
cells are a distinct population of human NK cells. We clustered for CD56, NKp46, 
NKp30, NKp44, NKG2A, NKG2C, and NKG2D on both primary and mbIL-21 
expanded human NK cells and found that NKp46 expression clusters into distinct 
NKp46+ and NKp46− NK populations and NKp46 expression overlaps with CD16 
expression (Figure 13c).  
 
  
Figure 13. Phenotype of NKp46- Human NK Cells. A) NKp46− NK cells are 
present in primary (mean = 21%) and K562 Clone 9.mbIL-21-expanded 
(mean = 21.7%) human NK cells (n = 4, median ± IQR shown). B) NKp46− NK 
cells have decreased expression of CD16, DNAM-1, Perforin, and NKG2D (n = 4, 
mean ± SD depicted). C) Spade clustering analysis of primary and mbIL-21 
expanded human NK cells for CD56, NKp46, NKp30, NKp44, NKG2C, NKG2D, 
and NKG2A revealed that NKp46 and CD16 cluster together (outlining delineates 
cells that stain positive for the indicated marker). Mass Cytometry samples were 
prepared by Arianexys Aquino-Lopez and data was analyzed by Jennifer Foltz. 
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2.2.6 NK Cells in Canine Osteosarcoma 
We obtained PBMC from canines that were not currently undergoing 
chemotherapy and found no difference in the percent of NK cells in OS-bearing 
canines compared to healthy controls (Figure 14a). Additionally, NK cells from OS 
patients had similar proliferation on K562 Clone 9.mbIL-21 feeder cells and 
cytotoxicity against three canine OS cell lines compared to healthy canines (Figures 
14b,c). 
 
  
C) 
A) B) 
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2.2.7 Cross-Reacting Antibodies 
To determine if commercially available antibodies to human and mouse NK 
cell proteins would cross-react with canine NK cells, we screened twenty-four 
different antibodies against expanded canine NK cells (Table 2). Of these, only 1 
antibody, anti-human DNAM-1 (clone DX11) was successful (Figure 15). Titration of 
this DNAM-1 antibody demonstrated that this antibody must be used at higher 
concentrations then specified by the manufacturer for adequate staining of canine 
NK cells. 
  
Figure 14. NK cell numbers, expansion, and function in canine 
osteosarcoma patients. Canine osteosarcoma patients have A) similar 
percentages of NK cells in lymphocytes, B) retain proliferative capacity in 
response to K562 Clone9.mbIL-21 feeder cells, and C) cytotoxicity against canine 
osteosarcoma cell lines when compared to healthy canines (median ± IQR for all). 
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Figure 15. Cross-Reacting DNAM-1 Expression on Canine CD3-/NKp46+ 
cells. Representative histogram of DNAM-1 expression on expanded CD3-
/NKp46+ cells is depicted. Percent of DNAM-1+ NK cells at Day 0 and in pure, 
expanded NK is shown (n=3). 
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Table 2. Screening of Mouse and Human Antibodies Recognizing NK Cell 
Proteins on Canine NK Cells. 
Protein Clone Species 
Specificity 
Cross-Reactive? 
NKp30 P30-15 Human No 
NKG2A/C/E 20D5 Mouse No 
NKG2D 1D11 Human No 
CD11a G43-25B Human No 
CD11b 44/ICRF44 Human No 
CD16 3G8 Human No 
CD16 B73.1 Human No 
CD94 131412 Human No 
Fas DX2 Human No 
CD62L  DREG-56 Human No 
CD57 NK-1 Human No 
DNAM-1 DX11 Human Yes 
FasL NOK-1 Human No 
CD244 2-69 Human No 
CCR6 11A9 Human No 
CCR7 150503 Human No 
CX3CR1 2A9-1 Human Not clear staining 
NKp80 4A4.D10 Human  No 
NKp80 239127 Human No 
NKp44 P44-8.1 Human No 
NKG2A FAB1059P Human No 
NKG2C FAB138P Human No 
Ly49C/I 5E6 Mouse No 
NKG2D CX5 Human  No 
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2.3 Discussion 
We sought to characterize canine NK cells and optimize their expansion for 
use as a comparative oncology model of NK immunotherapy of OS. To this end, we 
developed a monoclonal antibody specific to canine NKp46 and demonstrated that 
this antibody recognizes CD3−/NKp46+ cells that have striking phenotypic and 
functional similarity to human NK cells – expressing all of the NCRs and secreting 
IFNγ and TNFα. These CD3−/NKp46+ cells from both healthy and OS-bearing 
canines exhibit robust expansion with K562 Clone9.mbIL21 and canine IL-2 and are 
highly cytotoxic against OS. In addition, we identified a small population of NKp46− 
NK cells that have reduced cytotoxicity but similar cytokine secretion and can be 
induced to express NKp46. 
This antibody also identifies a subset of T-cells that are NKp46+.  In humans, 
NKp46+ T-cells are rare, but NKp46 can be acquired upon activation in γδ T-cells 
(160, 161). In bovines, NKp46+ T-cells have functional similarity to bovine NK cells 
as they were able to kill a tumor cell line spontaneously unlike T-cells that did not 
express NKp46 (162). We observed very little killing of the spontaneous OS lung 
metastasis cell line, Grey, by CD3+ canine T-cells, but it will be of interest to more 
fully characterize the phenotype and function of NKp46+ canine T-cells.  Despite the 
low cytotoxicity of the T-cells against the OS cell line, it remains unknown whether 
the contaminating T-cells in K562 Clone9.mbIL-21 expanded cell cultures are 
capable of mediating Graft-versus host disease. Substantial work in humans 
suggests that contaminating T-cells might mediate GVHD and be detrimental in an 
allogeneic transplant setting (163, 164). Thus to reduce this potential adverse effect 
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by contaminating T-cells, we demonstrate that CD3-depleted PBMC can give rise to 
greater than 96% pure CD3-/NKp46+ expanded NK cells.  
Spontaneous animal models of cancer for the study of NK cell therapies in a 
syngeneic setting have to date remained elusive due to difficulty in expanding NK 
cells in other species outside of human and the high cost of primate research.  
Instead, pre-clinical models of adoptive NK cell therapy have relied largely on 
infusing human NK cells into xenogeneic mouse models which lack a complete 
tumor microenvironment and an intact immune system that may influence the 
effectiveness of immune-based therapies (165, 166). We report here an improved 
expansion platform for canine NK cells on K562 Clone 9.mbIL-21 feeder cells 
obtaining a median fold expansion of over 20,000 in 3 weeks when supplemented 
with canine IL-2. To the best of our knowledge, this is the largest fold expansion of 
NK cells from any mammal outside of human, and is significantly greater than 
previously reported expansions of NK-like cells in canine (136, 139). Previous 
expansions of canine CD3- NK-like cells have reported an average fold expansion of 
140-fold in 3 weeks using cytokine alone (IL-2 and IL-15), 233-fold expansion in 2 
weeks with EL08-1D2 feeder cells following CD5 depletion, and 90-fold expansion 
with K562 feeder cells and soluble IL-2 , IL-15, and IL-21 in 3 weeks (136, 138). It 
will be of future interest to determine if the improved expansion of canine NK cells 
with mbIL-21 over mbIL-15 is also due to an increase in telomere length as we have 
previously demonstrated for human NK cells (165).   
Similar to Grondahl-Rosado et al., we found that NKp46 was not constitutively 
expressed on all CD3-/Granzyme B+ cells (156). In the present study, we added to 
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this knowledge, by finding that these NKp46-, Null cells could be induced to express 
NKp46 and have a distinct function- displaying reduced cytotoxicity compared to 
NKp46+ NK cells. In contrast to Grondahl-Rosado et al., we found here that NKp46- 
cells produce similar amounts of IFN-γ among all other cytokines tested. These 
differences may be explained by different cell stimulation as Grondahl-Rosado et al. 
measured IFN-γ stimulation after culturing NKp46+ and NKp46- cells together with 
human IL-2, IL-12, and IL-15 while, in this paper, we stimulated NKp46+ and NKp46- 
cells after sorting with canine IL-2 and K562 expressing membrane-bound IL-21 
(Figure 12b) (156).  
 NKp46- NK cells are not unique to canines, but have been previously 
reported in both porcine and humans, where NKp46 expression also discriminates 
human NK cells with reduced cytotoxicity. In contrast to our data in canine, porcine 
NKp46 discriminates NK cells with different IFN-γ secretion but not cytotoxicity (17, 
152). Similar to porcine NKp46- NK cells, NKp46 could be induced in canine NKp46- 
cells; however, NKp46 has not been inducible in human NKp46- cells (152). This 
may be due to differences in the regulation of NKp46 expression across species, 
where it is inducible in some species’ (porcine and canine) NK cells but not in 
human, or NKp46 expression may require specific signals that have not been 
described yet (17).  
We found phenotypic similarity between canine NKp46− null cells and both 
primary and K562 Clone9.mbIL-21-expanded NKp46− human NK cells 
(CD3−/CD56+). In humans, NKp46− NK cells are predominantly CD56dim. Expanded 
NKp46− cells in both species have reduced expression of NKG2D and CD16. Thus, 
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we speculate that NKp46− canine and human NK cells may represent similar 
subsets of NK cells in both species; however, additional functional and phenotypic 
characterizations of NKp46− NK cells are necessary to elucidate this cell type to 
determine if they are homologous. Primary human NK cells also have reduced 
expression of CD16, suggesting that this population of NKp46− NK cells is not an 
artifact of ex vivo expansion. There are several possible explanations for this cell 
type in humans that will be of interest to explore in future studies. 
CD56dim/CD16−/NKp46− cells may represent an intermediate step in NK cell 
maturation between CD56bright/CD16low/−/NKp46+ and CD56dim/CD16+/NKp46dim NK 
cells, or CD56dim/NKp46−/CD16− cells may be an exhausted NK cell population that 
were formerly CD56dim/CD16+/NKp46+ cells and have downregulated CD16 and 
NKp46 because of senescence. 
Contrary to human OS patients, we found no significant difference in 
circulating NK cells in canine OS compared to healthy canines (74). It will be of 
future interest to determine if these primary NK cells are functionally impaired, which 
would be facilitating tumor growth and has been found in several human cancers 
(167, 168). However, our data demonstrates that expanded NK cells from canine OS 
patients are active against OS, both primary and metastatic cell lines. This parallels 
findings in human OS where cytokine-activated NK cells from human OS patients 
have similar cytotoxicity against both OS cell lines and autologous patient-derived 
biopsies compared to healthy controls (9). Based on these findings, autologous NK 
cells may be effective in canine OS. 
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The human leukemia cell line, K562, has proven to be immune-stimulatory for 
canine T-cells, B-cells, and NK cells (123, 137-139, 169). Interestingly, similar to 
what we observed for canine NK cells having optimal proliferation with canine IL-2 
over human IL-2, canine B-cells also required species-specific IL-4 for their 
expansion (169). It is beneficial to the translation of adoptive immune therapies from 
canine to human that the same cell line used for the generation of human based 
immune therapies can be used for similar canine therapies with very slight 
modifications. 
In summary, our study furthers the understanding of the canine NK cell 
phenotype and function. Furthermore, we describe the largest expansion of NK cells 
from another mammal besides humans, using K562 Clone 9.mbIL-21 feeder cells 
and canine IL-2. These mbIL-21 expanded NK cells are highly cytotoxic against OS 
cell lines, suggesting potential for immunotherapy of dogs with OS and potential for 
therapeutic use in other canine cancers such as lymphoma, leukemia, melanoma, 
and glioblastoma. This approach will allow for the study of NK cell therapy in an 
immune-intact, outbred, and spontaneous animal model. Many of these cancers 
progress rapidly in canines, allowing for rapid testing of NK cell therapies, which is of 
particular interest in rare and pediatric cancers such as OS where trial accrual is 
slow. These results support the development of canine NK cell trials to help prioritize 
the most promising treatment regimens for human clinical trials. Of particular interest 
is a trial of intratumoral injection of canine NK-like cells expanded on K562 
Clone9.mbIL-21 feeder cells after radiation therapy in canine OS that is currently 
underway (UC Davis, Michael Kent & Bob Canter). The effectiveness of canine NK 
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cells in combination with other agents, such as cytokines, chemotherapy, and 
antibodies, will be of particular interest. 
Chapter 3: Education of NK cells to be TGFβ Resistant 
3.1 Background 
Immune therapy holds great promise for improving the outcome of cancers 
such as OS, where survival has not improved over the last 30 years. OS, including 
chemotherapy-resistant OS, is readily killed in vitro by both autologous and 
allogeneic activated NK cells. However, the tumor microenvironment in OS, and 
other solid tumors, has elevated levels of the highly immunosuppressive cytokine, 
transforming growth factor-beta 1 (TGFβ) (94, 95). In fact, OS cells secrete TGFβ 
and TGFβ levels are elevated in the presence of metastatic disease (91, 95, 170). 
The addition of a blocking antibody to TGFβ improved the efficacy of a dendritic cell 
vaccine in OS (171), providing proof of principle that TGFβ is actively inhibiting 
immune therapies in OS.  
TGFβ is part of a family of ligands and receptors that also include the bone 
morphogenic proteins (BMP), activins, and inhibins. TGFβ’s suppression of NK cell 
function is multi-faceted. TGFβ modulates the development of NK cells and 
subsequently negatively affects their function upon reaching maturation. TGFβ 
promotes an immature NK cell lineage, by preventing the progression of NK cells 
into CD16+ NK cells. CD16 identifies mature, cytolytic NK cells. TGFβ can also 
induce formerly CD16+ NK cells to become CD16- (172). In addition, mice expressing 
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a dominant negative TGFβR on NK cells have increased numbers of mature NK 
cells compared to wild-type mice (173-175).  
In mature NK cells, TGFβ inhibits anti-tumor activity through multiple 
mechanisms. TGFβ decreases IL-2 and IL-15 induced NK cell proliferation (87, 176), 
and IL-15 induced mTOR activation (174). TGFβ also inhibits IFNγ secretion, which 
is important for stimulating the adaptive immune system and can sensitive tumors to 
NK cell lysis. TGFβ inhibits IFNγ both directly and indirectly. SMAD3 directly binds to 
the IFNγ promoter and can also inhibit IFNγ indirectly by decreasing expression of 
the IFNγ-promoting transcription factors, T-bet and E4BP4 (99, 100, 177). However, 
TGFβ mediated inhibition of IFNγ secretion can be partially alleviated by pre-
incubation of NK cells with IL-12, IL-15, or IL-18 (100). Furthermore, TGFβ also 
inhibits TNFα and GM-CSF secretion and modulates chemokine receptor expression 
to promote the retention of NK cells within the bone marrow (97).  
Specifically, TGFβ mediates its’ inhibition of NK cell cytotoxicity by decreasing 
Granzyme and Perforin secretion, and expression of the following activating 
receptors: NKG2D, NKp30, KIRs, DNAM-1, NKp44, TRAIL, and CD16. This therein 
inhibits NK cell recognition of malignant cells expressing their cognate ligands. Cell-
surface expression of NKG2D, NKp30, and NKp44 is inhibited by downregulation of 
DAP10 and DAP12 adaptor proteins required for cell-surface expression (87, 96, 
101, 172, 176, 178-181).  
In NK cell biology, the roles of the other TGFβ family ligands and receptors 
have been less extensively studied, but have distinct characteristics from TGFβ. The 
activin family is suppressive like TGFβ but activin only suppresses NK cell cytokine 
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secretion and proliferation; and not cytotoxicity (182-184). In contrast to TGFβ and 
activin, BMP ligands enhance NK cell cytotoxicity and cytokine production (185). 
TGFβ signaling pathways are grouped into canonical signaling which is 
SMAD-dependent and non-canonical signaling pathways which are SMAD-
independent. For both canonical and non-canonical signaling, TGFβ homodimers 
bind to TGFβRI and TGFβRII, causing phosphorylation of TGFβR1 by TGFβRII. 
TGFβR1 subsequently phosphorylates SMAD2 and SMAD3 at serine residues 
thereby facilitating their binding to SMAD4. Complexes of SMAD2 or SMAD3 with 
SMAD4 translocate to the nucleus where they act on their target genes, such as 
IFNγ in NK cells. SMAD2 and SMAD3 are highly structurally similar, and often have 
redundant functions. However, SMAD3 can directly bind to DNA without SMAD4, 
whereas SMAD2 requires complex formation with SMAD4 to mediate DNA-binding 
(99, 100, 102, 110). In addition, in Th17 cells, SMAD2 and SMAD3 have strikingly 
different functions with SMAD2 promoting STAT3 activation, which is necessary for 
Th17 cell development, while SMAD3 inhibits STAT3 activation (186). Non-canonical 
TGFβ signaling includes several pathways such as Rhoa, PI3K/AKT, Erk, and MAPK 
pathways (102).  
TGFβ signaling can be inhibited by SMAD6 and SMAD7. SMAD6 inhibits 
SMAD1 which is activated in response to BMP signaling. SMAD6 also inhibits the 
non-canonical TGFβ pathway. SMAD7 promotes SMURF mediated ubiquitination of 
TGFβRs, leading to degradation. SMAD7 can also inhibit BMP signaling. IFNγ and 
TNFα activate SMAD7 to antagonize TGFβ (187-189). 
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There have been several approaches towards generating NK and T-cells 
resistant to TGFβ. These include dominant negative TGFβRII expressing cells and 
combination therapies using TGFβ small molecule inhibitors with immune-based 
therapies. Importantly, all of these methods have demonstrated increased in vitro 
and in vivo efficacy of NK and T-cell therapies (101, 190-197). However, broad 
spectrum inhibition of TGFβ has potential for adverse side effects; since TGFβ 
signaling is context dependent and can have both tumor-promoting and tumor-
suppressive effects. For example, the inhibition of TGFβ in murine models increased 
the number of circulating tumor cells (102), and broad spectrum inhibition of TGFβ 
causes profound autoimmune disease (198). Therefore, inhibition of TGFβ should be 
done only with caution and after determining the tumor’s responsiveness to TGFβ. 
Thus, non-systemic methods of generating innate TGFβ resistance are a promising 
alternative to avoid the adverse effects that systemic TGFβ inhibition may have.  
The Lee Lab has developed a platform for expanding human NK cells using 
K562 feeder cells expressing 41BBL and membrane-bound IL-21. These NK cells 
expand on average 30,000-fold in 3 weeks and are highly cytotoxic against tumors 
of all types, including OS. However, they remain sensitive to suppression by TGFβ, 
and thus, the effectiveness of adoptive NK cell therapy remains suboptimal. 
Thus, the goal of this aim was to develop an approach towards generating NK 
cells that have intrinsic resistance to TGFβ suppression of NK anti-tumor function. 
To this end, we hypothesized that expanding NK cells in the presence of TGFβ with 
K562 feeder cells expressing membrane-bound IL-21 would inhibit the growth of NK 
cells that are sensitive to TGFβ suppression and allow for NK cells with reduced 
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sensitivity to TGFβ to grow, since NK cells have a range of sensitivity to TGFβ(175). 
We hypothesized that this would result in less NK cells post-expansion than our 
Standard approach (without TGFβ), but that the TGFβ expanded NK cells- Resistant 
NK cells (ReNK), would have improved anti-tumor function and reduced sensitivity to 
TGFβ. 
3.2 Results 
3.2.1 ReNK cells have similar proliferation compared to Standard NK cells. 
Surprisingly, ReNK cells had similar overall 2 week proliferation compared to 
Standard NK cells. However, ReNK cells had significantly decreased proliferation 
during the first week (p=0.01). We also observed that during the 2nd week of 
expansion ReNK cells had a trend towards increased proliferation compared to 
Standard NK cells (p=0.08) (Figure 16). 
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3.2.2 ReNK cells retain high cytolytic capacity. 
Next, we wanted to determine the anti-tumor function of ReNK cells. ReNK 
cell anti-tumor response was measured by a 3-hour degranulation assay for 
CD107a. To this end, NK cells were incubated with tumor cells with CD107a 
antibody and monensin to block degradation of CD107a. ReNK cells had 
significantly increased degranulation both in the presence (R/+) and absence (R/-) of 
TGFβ against DAOY and MG63, but no significant difference in degranulation 
against HOS. Interestingly, degranulation was only inhibited in Standard NK cells in 
the presence of TGFβ against HOS (S/+), but not DAOY or MG63 cells (Standard 
Expansion/No TGFβ= S/-) (Figure 17) (Mean ± SD, MG63: S/-= 11.3 ± 3.5, S/+= 9.0 
± 3.1, R/-= 21.9 ± 9.8, R/+= 20.5 ± 9.7; HOS: S/-= 28.1 ± 16.1, S/+= 24.3 ± 13.7, R/-
Figure 16. Proliferation of  ReNK cells. ReNK cells have decreased 
proliferation in the 1st week of expansion, but a trend towards 
increased proliferation in the 2nd week of expansion.  
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= 32.8 ± 12.2, R/+= 31.2 ± 9.9; DAOY: S/-= 14.0 ± 7.8, S/+= 11.0 ± 6.4, R/-= 37.2 ± 
17.3, R/+= 37.5 ± 16.3).  
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  Figure 17. ReNK cells have increased degranulation. Day 14 
Expanded NK cells were rested overnight with or without 10 ng/mL TGFβ, 
and then cultured with tumor cells for 3 hours to assess degranulation. 
ReNK cells have increased degranulation against DAOY and MG63 plus 
and minus TGFβ treatment. Degranulation is not significantly different 
between Standard and ReNK cells against HOS. Median ± IQR depicted 
(n=4-6 donors). 
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Since degranulation does not always correlate with tumor cell death, we next 
assessed tumor cell lysis by ReNK and Standard NK cells. To this end, ReNK and 
Standard NK cells were rested overnight in the presence or absence of 10 ng/mL of 
TGFβ and then co-cultured with calcein-AM labeled tumors for a 4-hour cytotoxicity 
assay under the same conditions as the degranulation assay. Preliminary data in the 
lab found that ReNK cells had increased cytotoxicity in both the presence and 
absence of TGFβ against the medulloblastoma cell line, DAOY. ReNK had less 
inhibition by TGFβ (Figure 18a), and increased cytotoxicity (Figure 18b).  
 
 
 
 
 
 
A) B) 
Figure 18. ReNK cells have increased killing of DAOY. Expanded NK cells 
were rested overnight plus or minus TGFβ and A) ReNK cells were found to 
have decreased sensitivity to TGFβ and to B) kill better than Standard NK 
cells in the presence and absence of TGFβ (n=6). 4/6 donors were used with 
permission from Geoffrey Kannan. 
58 
 
We wanted to extend these findings to OS. Against OS cell lines MG63 and 
HOS, ReNK cells had decreased cytotoxicity without TGFβ in the media compared 
to Standard NK cells (Figure 14a) (MG63: S/-= 65.8 ± 12.6 S/+= 53.6 ± 14, R/-= 
51.6 ± 9.2, R/+= 58.5 ± 10.2; HOS: S/-= 85.2 ± 7.2 S/+= 74.7 ± 15.5, R/-= 63.4 ± 9.1, 
R/+= 68.7 ± 11.5). There was no decrease in killing in the presence of TGFβ for 
ReNK. Unexpectedly, ReNK cells killed MG63 significantly better in the presence of 
TGFβ than without TGFβ.  
To extend these findings to other tumors, we tested ReNK cells against the 
medulloblastoma cell lines, D283 and D425. Against these cell lines, cytotoxicity was 
variable with ReNK cells having similar cytotoxicity in all conditions against D425, 
but reduced cytotoxicity against D283 cells (Figure 19) (D283: S/-= 61.1 ± 11.9, 
S/+= 52.9 ± 6.7, R/-= 17.8 ± 6.4, R/+= 30.1 ± 6.5; D425: S/-= 60.1 ± 12.8 S/+= 51.0 
± 5.2, R/-= 42.4 ± 4.7, R/+= 40.4 ± 11.1). Interestingly, Standard NK cell cytotoxicity 
in the presence of TGFβ was only significantly inhibited against MG63 and DAOY, 
with HOS, D283, and D425 exhibiting a trend towards decreased cytotoxicity. As 
with MG63, ReNK cells killed D283 significantly better in the presence of TGFβ than 
without. 
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  Figure 19. ReNK cells have variable cytotoxicity. Day 14 Expanded 
ReNK cells have decreased killing in the absence of TGFβ against MG63, 
HOS, and D283. ReNK cells have decreased cytotoxicity in the presence of 
TGFβ against D283, but similar killing against all other cell lines in the 
presence of TGFβ. Median ± IQR shown (n=3-7 donors). 
A) 
 
 
 
 
 
B) 
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Since ReNK cells killed MG63 and D283 more efficiently in TGFβ than without 
TGFβ, we hypothesized that receptor expression may be changed in the overnight 
treatment of the Standard and ReNK cells. To this end, we assessed the cell surface 
expression of TRAIL, NKG2D, and FasL; and the intracellular expression of 
Granzyme A, Granzyme B, and Perforin. We observed no significant differences in 
Standard NK cell expression of TRAIL, FasL, Granzyme A, Granzyme B, or Perforin 
with overnight treatment with TGFβ. However, we did observe a trend towards 
decreased NKG2D expression level (MFI) in Standard NK cells rested overnight in 
TGFβ that did not reach significance, likely because of the low sample number 
(Figure 20a) (% Positive- TRAIL= S/-: 28.3 ± 11.6, S/+ 29.7 ± 11.0, NKG2D= S/-: 
99.8 ± 0.1, S/+ 99.4 ± 0.3, FasL= S/-: 20.4 ± 5.0, S/+ 19.8 ± 7.5, Granzyme A= S/-: 
100 ± 0, S/+: 100 ± 0, Granzyme B= S/-: 57.3 ± 10.3, S/+ 58.6 ± 12.5, Perforin= S/-: 
99.8 ± 0, S/+: 99.3 ± 0.4; MFI- TRAIL= S/-: 557 ± 285, S/+ 566 ± 297, NKG2D= S/-: 
11545 ± 3406, S/+ 6022 ± 1019, FasL= S/-: 231.6 ± 33, S/+: 216.8 ± 73, Granzyme 
A= S/-: 8433 ± 1058, S/+: 7217 ± 919, Granzyme B= S/-: 547.4 ± 120.4, S/+ 561 ± 
127, Perforin= S/-: 5172 ± 737, S/+: 3927 ± 922).  
In ReNK cells, we observed a slight statistically significant decrease in the 
percentage of NK cells expressing cell surface FasL with TGFβ treatment. We did 
not observe any differences in expression of other proteins in ReNK cells rested 
overnight in TGFβ (Figure 15) (% Positive- TRAIL= R/-: 50.8 ± 14.1, R/+ 53.9 ± 12.1, 
NKG2D= R/-: 99.9 ± 0.1, R/+ 99.7 ± 0.4, FasL= R/-: 64.1 ± 12.0, R/+ 60.3 ± 11.9, 
Granzyme A= R/-: 99.9 ± 0, R/+: 99.8 ± 0, Granzyme B= R/-: 49.0 ± 14.7, R/+ 50.4 ± 
20.2, Perforin= R/-: 97.1 ± 1.6, R/+: 94 ± 1.1; MFI- TRAIL= R/-: 50.8 ± 14.1, R/+ 53.9 
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± 12.1, NKG2D= R/-: 99.9 ± 0.1, R/+ 99.7 ± 0.4, FasL= R/-: 64.1 ± 12.0, R/+ 60.3 ± 
11.9, Granzyme A= R/-: 99.9 ± 0, R/+: 99.8 ± 0, Granzyme B= R/-: 49.0 ± 14.7, R/+ 
50.4 ± 20.2, Perforin= R/-: 97.1 ± 1.6, R/+: 94 ± 1.1; MFI- TRAIL= R/-: 1045 ± 459, 
R/+: 1141 ± 420, NKG2D= R/-: 10671 ± 1267, R/+: 8148 ± 2634, FasL= R/-: 685 ± 
147, R/+: 639 ± 138, Granzyme A= R/-: 5864 ± 196, R/+: 5561 ± 288, Granzyme B= 
R/-: 480 ± 157, R/+ 505 ± 221, Perforin= R/-: 1727 ± 226, R/+: 1331 ± 141) (Figure 
20b). 
 
 
 
 
 
Figure 20. Effect of Overnight TGFβ Treatment on Standard and 
ReNK cell Receptor Expression. Overnight TGFβ treatment decreases 
MFI for Perforin and NKG2D in both Standard and ReNK.  In ReNK cells, 
TGFβ treatment has a slight but significant decrease in FasL+ NK cells 
(n=2-3). 
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3.2.3 ReNK cells have increased cytokine secretion. 
IL-6, IFNγ, and TNFα are three cytokines that can inhibit TGFβ signaling 
(199). In turn, TGFβ is also able to inhibit NK cell IFNγ and TNFα secretion. We first 
assessed mRNA levels of IFNγ, TNFα, and IL-6 at Day 14 of expansion in Standard 
and ReNK cells using qPCR. No significant difference was observed (Figure 21) 
(Fold Change of ReNK= IFNγ: 2.1 ± 2.5, TNFα: 0.7 ± 0.3, IL-6: 1.1 ± 1.0, n=5 for 
IFNγ, n=4 for IL-6 & TNFα).  
  
Next, we wanted to determine if ReNK cells produce more IL-6, IFNγ, and 
TNFα producing NK cells upon co-culture with tumor cells using intracellular flow 
cytometry. After 3 hours, we found that basal IL-6 production (no tumor target) was 
significantly elevated in ReNK cells in both the presence and absence of TGFβ 
(Figure 22a) (S/-= 19.4 ± 5.1, S/+= 18.8 ± 6.0, R/-= 24.8 ± 8.3, R/+= 24.1 ± 8.7). For 
HOS, IL-6 anti-tumor production was not significantly different in any of the groups; 
however, against MG63, IL-6 was significantly elevated in ReNK cells both with and 
without TGFβ (Figure 22b) (HOS: S/-= 12.2 ± 6.6, S/+= 11.1 ± 5.8, R/-= 13.1 ± 6.7, 
R/+= 13.5 ± 7.2; MG63: S/-= 8.4 ± 1.2, S/+= 8.5 ± 1.8, R/-= 10.8 ± 1.1, R/+= 10.7 ± 
Figure 21. Gene expression of TGFβ 
Antagonistic Cytokines. .Day 14 Expanded 
ReNK cells have similar gene expression for 
IFNγ, TNFα, and IL-6 as Standard NK cells. 
Median ± IQR depicted (n=4-5 donors). 
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A) 
 
 
 
 
 
B) 
1.3). Surprisingly, co-culture of both Standard and ReNK cells with either HOS or 
MG63 decreased the percentage of NK cells producing IL-6 compared to basal IL-6 
production.  
 
 
 
 
For IFNγ and TNFα, there was negligible production at baseline (no tumor 
target); therefore, for IFNγ and TNFα, the percentage of NK cells producing 
cytokines in response to tumor was normalized to the basal percentage of NK cells 
Figure 22. IL-6 Production of ReNK cells. A) ReNK cells have production of 
IL-6 without stimulation, B) and increased anti-tumor IL-6 production against 
MG63, but not HOS. Median ± IQR (n= 4-5 donors). 
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producing the cytokine without target (Anti-tumor cytokine production= % NK 
producing cytokine with target minus % NK producing cytokine with no target). We 
found a significant increase in the percentage of IFNγ and TNFα producing NK in 
ReNK cells without TGFβ for MG63, HOS, and DAOY. In addition, there was 
significantly increased IFNγ and TNFα producing NK cells in the presence and 
absence of TGFβ in ReNK cells compared to Standard NK cells against MG63 and 
HOS. We also observed a slight, but significant decrease in IFNγ producing ReNK 
cells with TGFβ compared to no TGFβ for MG63. DAOY had significantly increased 
TNFα producing ReNK cells in the presence of TGFβ, and a trend towards 
increased IFNγ producing ReNK cells with TGFβ (Figure 23a, 24a). (IFNγ- MG63: 
S/-= 7.5 ± 2.9, S/+= 6.6 ± 2.1, R/-= 19.1 ± 5.4, R/+= 17.3 ± 6.6; HOS: S/-= 20.1 ± 11, 
S/+= 18.2 ± 9.8, R/-= 41.6 ± 14.7, R/+= 38.2 ± 13.7; DAOY: S/-= 5.4 ± 4.5, S/+= 5.7 
± 5.3, R/-= 26.8 ± 19.2, R/+= 28 ± 19.5) (TNFα- MG63: S/-= 12.7 ± 5.6, S/+= 12.6 ± 
4.7, R/-= 20.2 ± 6.4, R/+= 19.2 ± 6.6; HOS: S/-= 27.8 ± 16.9, S/+= 28.6 ± 15.7, R/-= 
38.1 ± 15.6, R/+= 36.9 ± 15.5; DAOY: S/-= 8.9 ± 4.8, S/+= 12.6 ± 8.7, R/-= 27.3 ± 
14.5, R/+= 28.9. ± 14.2).  
Next, we wanted to determine if IFNγ+ and TNFα+ ReNK cells had higher 
production of IFNγ and TNFα than Standard NK cells. ReNK cells had increased 
cytokine production as measured by MFI in both IFNγ+ or TNFα+ NK cells both plus 
and minus TGFβ compared to Standard NK cells against MG63 and HOS. For 
DAOY, ReNK cells produced more TNFα both plus and minus TGFβ and more IFNγ 
in the absence of TGFβ than Standard NK cells (Figure 23b, 24b). This suggests 
that ReNK cells not only have more cytokine producing NK cells but also produce 
65 
 
more cytokines per cell. (IFNγ- MG63: S/-= 1835 ± 524.8, S/+= 1851 ± 532.8, R/-= 
2657 ± 859.4, R/+= 2597 ± 819.2; HOS: S/-= 2352 ± 420, S/+= 2349 ± 436.7, R/-= 
3771 ± 1107, R/+= 3633 ± 1017; DAOY: S/-= 1584 ± 704.5, S/+= 1636 ± 696.6, R/-= 
2256 ± 586.9, R/+= 2241 ± 508.4) (TNFα- MG63: S/-= 1637 ± 444.5, S/+= 1672 ± 
451.4, R/-= 2479 ± 391.4, R/+= 2456 ± 408.7; HOS: S/-= 2279 ± 626.7, S/+= 2332 ± 
680.6, R/-= 3438 ± 819.5, R/+= 3428 ± 751.1; DAOY: S/-= 835.9 ± 100.1, S/+= 
883.5 ± 147, R/-= 1471 ± 431.5, R/+= 1432. ± 402.2).  
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Figure 23. ReNK cells have increased IFNγ production. A) ReNK cells have 
significantly increased IFNγ+ NK cells and B) IFNγ+ ReNK cells have increased 
expression of IFNγ than Standard NK cells both plus and minus TGFβ. Median ± 
IQR depicted (n=4-6 donors). 
A)       B) 
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A)      B) 
 
  
Figure 24. ReNK cells have increased TNFα+ production. A) ReNK cells 
have significantly increased TNFα+ NK cells and B) increased expression 
of TNFα compared to Standard NK cells both plus and minus TNFα. 
Median ± IQR (n=4-6 donors). 
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However, since TGFβ has been reported to inhibit secretion but not 
production of Granzymes, we next wanted to confirm that ReNK cells are actually 
secreting more IFNγ and TNFα. To this end, Standard and ReNK cells were 
incubated with tumor targets as described above and supernatants were collected to 
measure IFNγ and TNFα secretion with Cytometric Bead Array. For secretion, TGFβ 
did exhibit the expected inhibition of IFNγ secretion in the Standard expanded NK 
cells for MG63 but not for HOS and DAOY, nor did TGFβ significantly inhibit 
Standard or ReNK cell secretion of TNFα for any cell line. In ReNK cells, TGFβ 
inhibited ReNK cell secretion of IFNγ against MG63 and HOS. However, similar to 
the IFNγ and TNFα production data, we found a significant increase in IFNγ (HOS, 
MG63) secretion in both the presence and absence of TGFβ compared to Standard 
expanded NK cells (Figure 25, 26). (IFNγ- MG63: S/-= 133.3 ± 109.9, S/+= 75.8 ± 
73.4, R/-= 862.6 ± 420.7, R/+= 684.4 ± 392.4; HOS: S/-= 209.9 ± 267.5, S/+=97.9 ± 
129.6, R/-=1020  ± 562.9, R/+= 863.6 ± 498.1; DAOY: S/-= 57.4 ± 68.2, S/+= 35.1 ± 
57.7, R/-= 1197 ± 953.4, R/+= 1002 ± 903.3).  
TNFα was significantly increased in ReNK cells without TGFβ in MG63 and 
HOS, and significantly increased in the presence of TGFβ for MG63. ReNK cells had 
a trend towards increased IFNγ or TNFα secretion against DAOY (Figure 25, 26) 
(TNFα- MG63: S/-= 226.3 ± 60.9, S/+= 182.3 ± 32.7, R/-= 666.5 ± 178.8, R/+= 632.2 
± 121.9; HOS: S/-= 249.9 ± 126.1, S/+= 243.1 ± 46.3, R/-= 771.2 ± 139.3, R/+= 
836.8 ± 121.6; DAOY: S/-= 57.6  ± 49.9, S/+= 53.4 ± 51.5, R/-= 665.9 ± 513.1, R/+= 
567.3 ± 512.3). Thus, TGFβ in combination with IL-21 leads to NK cells with 
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increased anti-tumor IFNγ and TNFα secretion compared to Standard NK cells, 
expanded with IL-21 only.  
  
Figure 25. ReNK cells have increased IFNγ secretion. ReNK cells have 
increased IFNγ secretion compared to Standard NK cells, and have slight 
inhibition of  IFNγ secretion with TGFβ treatment against MG63 and HOS. 
Median ± IQR (n=4-6 donors). 
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Figure 26. ReNK cells have increased TNFα secretion. ReNK cells have 
significantly increased TNFα secretion with no TGFβ against MG63 and HOS 
and significantly increased TNFα secretion against MG63 in the presence of 
TGFβ. Median ± IQR (n=2-4 donors). 
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3.2.4 ReNK cells have altered NK cell Phenotype. 
Since TGFβ has been reported to decrease NK cell expression of NKG2D, 
NKp30, and DNAM-1, we assessed the expression of NK receptors on Day 14 
expanded NK cells using flow cytometry. As expected, ReNK cells had a significant 
decrease in the percent of NK cells expressing NKp30 and DNAM-1 (Figure 27) (% 
Positive= NKp30: S: 98.1 ± 1.0 R: 66.0 ± 10.2; DNAM-1: S: 93.1 ± 3.6 R: 84.0 ± 6.7; 
Fold Change of ReNK= NKp30: 0.19 ± 0.03, DNAM-1: 0.76 ± 0.17), and a significant 
decrease in fold change of expression level of NKp30 and DNAM-1 as measured by 
MFI (Figure 28). For NKG2D, no different in the percent of NK cells expressing 
NKG2D was observed; however, there was a significant fold decrease in NKG2D 
MFI compared to Standard NK cells (% Positive= NKG2D: S: 99.9 ± 0.2 R: 99.5 ± 
0.3; ReNK Fold Change: 0.70 ± 0.23). Surprisingly, ReNK cells had an increase in 
TRAIL and cell surface FasL positive NK cells and increased expression level of 
both TRAIL and cell surface FasL. However, there was no difference in expression 
of total FasL (cell surface + intracellular FasL) (Figure 27, 28) (% Positive= TRAIL: 
S: 23.8 ± 13.6 R: 48.6 ± 11.5; Cell Surface FasL: S: 4.5 ± 2.2 R: 18.4 ± 8.5; Total 
FasL: S: 92.2 ± 2.1 R: 87.0 ± 6.3; Fold Change of ReNK= TRAIL: 3.0 ± 2.0, Cell 
Surface FasL: 2.5 ± 0.8, Total FasL: 1.0 ± 0). 
Next, the expression of intracellular proteins important for NK cell cytotoxicity 
was measured. No significant difference in percent positive or expression level of 
Granzyme A or Granzyme B was observed; however, ReNK cells had decreased 
expression level of Perforin but not in the percent of Perforin+ NK cells (Figure 27, 
28) (% Positive= Granzyme A: S: 99.8 ± 0.4 R: 99.9 ± 0.1; Granzyme B: S: 61.9 ± 
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28.0 R: 62.1 ± 25.0, Perforin: S: 98.9 ± 2.3 R: 96.6 ± 4.5; Fold Change of ReNK= 
Granzyme A: 0.8 ± 0.4, Granzyme B: 1.1 ± 0.4, Perforin: 0.5 ± 0.4). 
TGFβ has been reported to inhibit the expression of T-bet and GATA3 
transcription factors. In addition, RUNX3, GATA3, and T-bet can modulate IFNγ 
secretion; therefore, we next determined the transcription factor profile of ReNK cells 
at Day 14 of expansion. No difference was observed in percent positive or MFI for 
GATA3. For T-bet, no difference in percent of T-bet+ NK cells was observed; 
however, ReNK had decreased expression level of T-bet as measured by MFI 
(p<0.001). RUNX3 MFI had a trend towards increased MFI in ReNK, but no change 
in percent of RUNX3+ NK cells (Figure 29) (% Positive= RUNX3: S: 90.4 ± 4.7 R: 
82.9 ± 12.5, T-bet: S: 97 ± 2.3 R: 90.1 ± 8.8, GATA3: S: 97.1 ± 3.1 R: 92.7 ± 7.6; 
MFI= RUNX3: S: 18106 ± 4441 R: 22080 ± 6124, T-bet: S: 14787 ± 7173 R: 8806 ± 
4419, GATA3: S: 6400 ± 2070 R: 6527 ± 1758). 
  
Figure 27. ReNK cells have altered cell surface phenotype. ReNK cells have 
increased expression of the death receptors, TRAIL and FasL, but decreased 
expression of NKp30 and DNAM-1. ReNK cells have similar numbers of NKG2D+ 
cells, but decreased level of NKG2D expression. Shown is representative 
histograms from 1 donor of 5-7 independent donors (Blue: ReNK, Black: 
Standard). 
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Figure 28. Intracellular Protein Expression. ReNK cells have similar 
percentages of Granzyme A, Granzyme B, and Perforin expressing NK cells, but 
have decreased level of Perforin expression. Representative histogram from one 
donor of 7 independent donors is shown. 
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3.2.5 ReNK cells have changes in TGFβ Signaling. 
To determine if expansion with TGFβ and the development of relative TGFβ 
resistance was associated with alterations in the TGFβ pathway, Day 14 expanded 
NK cells were assessed for the mRNA levels of 92 genes in the canonical and non-
canonical TGFβ pathway (Appendix B). Of these 92 genes, 12 were found to be 
significantly decreased in all 4 donors: SMAD3, TGFBR3, TGFB1, RBL2, 
MAP3K7IP1/TAB1, LEFTY2, FMOD, MAP3K7/TAK1, BMP6, SMAD1, LTBP2, and 
TGFB3 (see Appendix B for all of the genes & p-values) (Fold change relative to 
Standard Expansion, all Mean ± SD; SMAD3= 0.03 ± 0.01, TGFBR3= 0.16 ± 0.07, 
TGFB1= 0.73 ± 0.07, RBL2= 0.76 ± 0.06, BMPP6= 0.30 ± 0.34, FMOD= 0.21 ± 0.34, 
LEFTY2= 0.48 ± 0.12, LTBP2= 0.30 ± 0.40, MAP3K7/TAK1= 0.72 ± 0.13, 
MAP3K7IP1/TAB1= 0.74 ± 0.06, SMAD1= 0.60 ± 0.21, TGFB3= 0.68 ± 0.18),. GDF7 
was decreased in 3 donors, but not detectable in the 4th donor (GDF7= 0.17 ± 0.29). 
Only SMAD6 was significantly increased (Figure 30a) (SMAD6= 6.30 ± 1.63). Of the 
significantly different genes, the highest expressed in Standard NK cells and with the 
most significant p-value were SMAD3 (p<0.0001) and TGFBR3 (p=0.0002) (Figure 
30b).  
The function of SMAD3 as a suppressor of NK cell anti-tumor function has 
been very clear. SMAD3 binds directly to the IFNγ promoter to inhibit IFNγ 
Figure 29. Transcription factor profile of ReNK cells. ReNK cells 
have decreased expression of T-bet compared to Standard NK cells, 
and a trend towards increased Runx3 expression.  
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expression and SMAD3-/- mice have enhanced NK cell function and decreased 
tumor growth. Thus, we wanted to determine if SMAD3 is also decreased at the 
protein level. Using western blot, we found that ReNK cells have no detectable 
SMAD3 protein in contrast to Standard NK cells where SMAD3 was readily 
detectable. On the contrary, both Standard and ReNK cells have similar levels of 
SMAD2 protein (Figure 30c). This is in agreement with other studies where SMAD3 
is particularly important in TGFβ inhibition of NK cell function. 
  
Figure 30. ReNK cells have altered TGFβ Pathway. A) ReNK cells had 
significantly different expression of 13 genes in the TGFβ pathway. B) 
Relative expression of the 13 genes was determined by subtracting the Ct 
value of the target gene from the Ct value of GAPDH to determine how 
highly expressed each of the target genes were in NK cells. Of the 13 
genes, SMAD3 and TGFBR3 (circled in green) were the highest expressed 
and with the greatest difference between ReNK and Standard NK cells. C) 
ReNK (R) cells also have decreased SMAD3 protein compared to 
Standard (S) NK while they maintain SMAD2 protein. WB were run by Nitin 
Chakravarti, samples prepared by Jennifer Foltz. 
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C) 
 
3.2.6 ReNK cells have increased STAT3 response. 
Previous data from our lab demonstrated that STAT3 signaling promotes NK 
cell proliferation, NKG2D expression, and enhances anti-tumor cytokine secretion, 
when compared to IL-15/STAT5 signaling (66, 200). TGFβ cooperates with IL-21 to 
drive development of Th17 cells by increasing STAT3 activity. Therefore, we wanted 
to determine if IL-21 and TGFβ was increasing STAT3 signaling in ReNK cells. 
STAT3 activity was measured by treating NK cells plus or minus 20 ng/mL IL-21, a 
dose we previously reported to lead to phosphorylation of STAT3 (Y705). We found 
that ReNK cells have significantly increased STAT3 phosphorylation compared to 
Standard expanded NK cells (p=0.0095), but similar levels of total STAT3 protein 
(Figure 31). 
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3.2.7 Persistence of ReNK Phenotype & Function. 
Next, we wanted to determine the persistence of ReNK cell phenotype and 
function. To this end, ReNK and donor-matched Standard NK cells were rested in 
low-dose IL-2 alone (e.g. ReNK were removed from TGFβ) after completion of 2 
Figure 31. ReNK cells have increased STAT3 response. A) NK cells were 
treated plus or minus 20 ng/mL IL-21 for 30 minutes (S: Standard, R: Resistant 
Expansion) B) ReNK (R) cells have increased phosphorylation of STAT3 (Y705), 
but similar levels of total STAT3. WB were run by Adam Studebaker, samples 
prepared by Jennifer Foltz. 
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weeks of expansion. ReNK cells were assessed for secretion of IFNγ and TNFα and 
cytotoxicity against DAOY and MG63 every 7 days during expansion and at 7 days, 
21 days, and 33 days (DAOY only) post-expansion. At 7 days of expansion, ReNK 
cells had significantly decreased TNFα secretion against MG63; but, after 14 days of 
expansion, ReNK cells had increased cytokine secretion, consistent with what we 
described earlier. In addition, we found that for DAOY, IFNγ and TNFα secretion 
increased from Day 7 to Day 14 for ReNK cells only, while Standard expanded NK 
cells trended towards decreased cytokine secretion, although this did not reach 
statistical significance most likely due to only 2 donors. After expansion, ReNK cells 
maintained their increase in IFNγ and TNFα secretion at both baseline and with 
TGFβ treatment at least 33 days post-expansion. Slight sensitivity to TGFβ for IFNγ 
secretion became evident at 33 days post-expansion against DAOY (Figure 32).  
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Figure 32. Cytokine Secretion of ReNK cells during and post-
expansion. ReNK cells maintain increased IFNγ and TNFα secretion at 
least 33 days post-expansion, but display slight suppression of IFNγ 
secretion with overnight TGFβ treatment at 33 days post-expansion. 
Median ± range is depicted. (n=2). 
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For cytotoxicity, ReNK cells had increased cytotoxicity against DAOY in both 
donors in the presence of TGFβ at Day 14 of expansion, and this effect persisted at 
least 33 days post-expansion. ReNK cell cytotoxicity against DAOY without TGFβ 
treatment was increased in both donors at 21 and 33 days post-expansion, with 
variable cytotoxicity at the other time points. However, ReNK cell increased 
cytotoxicity against DAOY was more evident at 2.5 E:T ratio compared to 5:1 E:T 
ratio. Against DAOY, ReNK cells lost their resistance to TGFβ at 33 days of resting; 
however, they remained more cytotoxic than Standard NK cells (Figure 33a). 
As the NK cells from both the Standard and Resistant expansion had a 
decrease in cytolytic activity after expansion, we were unable to assess cytotoxicity 
for MG63 past 21 days of resting for Donor 22, and past 7 days of resting for Donor 
25 due to loss of ability to kill MG63. Cytotoxicity against MG63 was variable, with 
one donor demonstrating increased killing by ReNK cells, while the other donor did 
not (Figure 33b). 
 Next, we wanted to determine if ReNK cell lysis of a previously resistant cell 
line, D283, was altered upon removal from TGFβ (Figure 19b). To this end, we 
found that D283 was killed significantly better 33 days after resting by ReNK cells in 
the absence of TGFβ. However, while ReNK cells still killed DAOY more efficiently in 
the presence of TGFβ, ReNK cells were suppressed by TGFβ to equivalent levels of 
killing as Standard NK cells despite higher baseline cytotoxicity in D283 at 33 days 
post-expansion (Figure 34).  
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Figure 33. Cytotoxicity of ReNK cells during Expansion and post-Expansion. 
A) ReNK cells have increased cytotoxicity against DAOY at 14 days of expansion 
and after expansion. ReNK cells lose their resistance to TGFβ suppression of 
cytotoxicity at Day 47. B) ReNK cells have decreased cytotoxicity without TGFβ 
against MG63, and both Standard and ReNK cells lose their ability to kill MG63 
quickly after expansion. Mean ± SD depicted for each individual donor. 
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Next, we wanted to determine how the ReNK cell phenotype changed after 
removal from TGFβ, and if the receptor expression correlated with the changes in 
cell lines sensitivity to ReNK cell lysis post-expansion. To this end, we measured 
expression of NKG2D, NKp30, DNAM-1, FasL, TRAIL, Granzyme A, Granzyme B, 
and Perforin using flow cytometry. Both the percentage of NK cells expressing 
TRAIL and cell surface FasL and the fold change of expression level decreased in 
Standard and ReNK cells after expansion. Notably, the increase in death receptor 
expression observed in ReNK cells during expansion was no longer present after 
expansion. In fact, cell Surface FasL expression was barely detectable 7 days after 
expansion (Figure 35, 36).  
The expression of DNAM-1 was increased in ReNK after removal from 
expansion conditions. The percentage of NK cells positive for NKp30 increased to 
the level of Standard NK cells; however, NKp30 was still expressed at lower density 
than in Standard NK cells (MFI). On the contrary, for NKG2D which was previously 
expressed at a lower level in ReNK cells, was expressed at a higher level than in 
Figure 34. Cytotoxicity of ReNK cells after 21 and 33 days resting. 
ReNK cells kill DAOY with increased efficiency compared to Standard NK 
cells at both 21 and 33 days resting; however, ReNK cells become 
suppressed by overnight TGFβ treatment after 21 days. ReNK cells kill 
D283 with increased efficiency, which was previously resistant, at 33 
days post-expansion; however, ReNK cells are sensitive to TGFβ 
treatment against D283 targets. Mean ± SD depicted for each individual 
donor. 
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Standard NK cells after ReNK removal from TGFβ. For intracellular proteins, we 
found that ReNK cells had reduced Granzyme A, Granzyme B, and Perforin (MFI) 
despite removal from TGFβ for 3 weeks. Unexpectedly, the percentage of NK cells 
expressing Granzyme B decreased after expansion in both groups; and this 
decrease was much larger in the ReNK cells compared to the Standard NK cells 
(Figure 35, 36).  
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Figure 35. Percent of ReNK and Standard NK expressing different 
receptors during, and post-expansion. NKp30 expression in ReNK 
increases post-expansion, but Granzyme B and death receptor 
expression decreases after expansion. ReNK are shown in Blue, 
Standard NK in black, each line represents an individual donor. 
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Figure 36. Expression level of ReNK and Standard NK Receptors 
during and Post-expansion. ReNK cells have increased NKG2D 
after expansion, but decreased NKp30, Perforin, Granzyme A, and 
Granzyme B. Depicted is fold change of Geometric Mean normalized 
to donor-matched Standard NK. 
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3.3 Discussion 
In summary, human NK cells expanded with K562 mbIL-21 feeder cells plus 
TGFβ (ReNK) have reduced sensitivity to TGFβ, most likely through loss of one of 
the key TGFβ signaling proteins- SMAD3. ReNK cells have remarkably increased 
IFNγ and TNFα secretion against OS and medulloblastoma cell lines. In addition, 
Day 14 Expanded ReNK cells have increased cytotoxicity against DAOY, while other 
cell lines are resistant to ReNK cell lysis. However, this can be overcome by resting 
ReNK cells in IL-2, which causes ReNK cells to be able to kill previously resistant 
tumors with greater effectiveness than Standard NK. Finally, ReNK cells retain TGFβ 
desensitization at least 3 weeks post-expansion. 
TGFβ signaling in the immune system is context dependent. Other signals 
received by a cell in combination with TGFβ dictate the effect that TGFβ has on the 
cell’s development and function. For example, in T-cells, TGFβ promotes the 
development of anti-inflammatory regulatory T-cells (Tregs). However, TGFβ in 
combination with either IL-6 or IL-21, leads to the development of pro-inflammatory 
Th17 cells instead of anti-inflammatory Tregs. In addition, CD28 on T-cells or CD40 
on dendritic cells can inhibit TGFβ suppression (110). There is some evidence of this 
in NK cells where pre-treatment of NK cells with pro-inflammatory cytokines such as 
IL-12, IL-15, and IL-18, reduces TGFβ suppression of NK cells (100). It is not yet 
known if engagement of a cell surface receptor on NK cells can block TGFβ 
inhibition. In light of our previous work on STAT3’s enhancement of NK cell function 
and enhanced STAT3 response in ReNK cells, we propose that ligation of IL-21 
expressed on the K562 feeder cells when presented simultaneously with TGFβ may 
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block TGFβ mediated suppression. For example, in Th17 cell development, IL-21 
presented with TGFβ prolongs STAT3 activation, and STAT3 inhibits SMAD3 (186, 
201, 202). Conversely, SMAD2 promotes STAT3 activation (186). Importantly, 
STAT3 is required for Th17 cell differentiation, while STAT5 inhibits Th17 cell 
differentiation (203). Similar to Th17 cells, a CD8 T-cell subset termed Tc17 cells 
has been discovered that also requires IL-21 plus TGFβ. Tc17 and STAT3 signaling. 
Tc17 cells produce IL-21 and IL-17. However, in contrast to ReNK cells, both Th17 
and Tc17 cells have very low production of IFNγ and Tc17 cells have low cytotoxic 
activity (204). If STAT3 is necessary for the development of ReNK cells, expansion 
of NK cells with IL-15 will not be capable of generating ReNK (203).  
Another alternative pathway to the development of ReNK cells is TGFβ 
mediated augmentation of IL-21 signaling. In salivary gland innate lymphoid cells, 
TGFβ upregulates IL-21 receptor expression (205), and in CD4+ T-cells, TGFβ plus 
IL-21 stimulates increased production of IL-21 from T-cells than when either cytokine 
is administered alone (206). Thus, IL-21 in combination with TGFβ may be 
increasing autocrine IL-21 signaling, stimulating ReNK cells to secrete their own IL-
21 which subsequently binds to the increased levels of IL-21R on ReNK cell surface, 
thereby promoting STAT3 activation. STAT3 activation may then subsequently 
mediate epigenetic or microRNA changes that lead to enhanced intracellular 
response upon tumor contact. It is of future great interest to determine if enhanced 
IL-21/STAT3 signaling is causing ReNK cell development. 
Surprisingly, and in contrast to previous papers, TGFβ did not inhibit the 
overall 2 week proliferation of ReNK cells (87). However, we did observe 
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significantly reduced proliferation in the 1st week of expansion, suggesting that, 
TGFβ selected for NK cells with decreased sensitivity to TGFβ. The stimulation 
conditions used in previous papers for inducing proliferation (IL-2 and IL-15) and the 
time points may be key to the differences observed in proliferation. Previous 
measurements on TGFβ’s effect on NK cell proliferation examined short-term 
proliferation, and not 2 week proliferation (87, 174). We propose that TGFβ plus IL-
21 driven expansion selects for a specific subset of NK cells, potentially those that 
are SMAD3neg to survive. These SMAD3neg NK cells would be resistant to basal 
constitutive phosphorylation of SMAD3 from TGFβ in the cell culture media, allowing 
for increased proliferation (207). It will be interesting to determine if SMAD3neg NK 
cells are found naturally in PBMC. Sorting of SMAD3neg and SMAD3pos NK cells with 
SmartFlare mRNA probes would provide insight into whether SMAD3 dictates NK 
expansion kinetics in the presence of TGFβ. 
We observed cell-line dependent sensitivity to ReNK cell lysis. DAOY was the 
most sensitive to ReNK cell lysis displaying increased cytotoxicity in both the 
presence and absence of TGFβ treatment. On the other hand, ReNK cells had 
decreased cytotoxicity against MG63, HOS, and D283 without TGFβ treatment, but 
similar cytotoxicity with TGFβ treatment compared to Standard NK cells. Tumor 
sensitivity to ReNK cell lysis may be explained by differences in the contribution of 
certain activating receptors in tumor cell lysis. DAOY is known to be sensitive to 
death receptor-mediated killing which are highly expressed on ReNK cells (208, 
209). Interestingly, D283, which was killed significantly less in Day 14 expanded 
ReNK cells, was conversely killed significantly better by ReNK cells after removal 
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from TGFβ for 33 days (Section 4.8). This increase in killing by ReNK cells 
correlated with increased expression of NKp30 and NKG2D after TGFβ withdraw. 
Therefore, cell-line sensitivity to ReNK cell lysis may be predictable based upon the 
NK cell receptors required for tumor cell killing. Future experiments using receptor-
Fc proteins (i.e. NKG2D-Fc) to determine if the receptor’s ligand is expressed on the 
tumor and/or blocking the receptor on the NK cells will be beneficial to explain the 
differences in sensitivity to ReNK cell lysis, and to predict which tumor types would 
most benefit from ReNK cells. In addition, Anti-tumor function of ReNK cells was 
maintained after expansion. In contrast, Standard NK cells have a drastic reduction 
in cytotoxicity, IFNγ, and TNFα secretion. Another advantage of ReNK cells may be 
their maintenance of function after expansion. 
 The cytotoxicity assays presented here are limited to the measurement of NK 
cell killing within 4 hours, which is known to be biased towards 
performing/granzyme-mediated killing. Perforin/Granzyme-mediating cytotoxicity is 
observed very quickly since perforin release disrupts membrane integrity prior to 
triggering caspase activation. Loss of membrane integrity is necessary for 
measurement of cytotoxicity in the calcein-AM based method, because cytotoxicity is 
measured by the extent of dye that has released into the supernatant. On the 
contrary, loss of membrane integrity is a late event in death receptor mediated 
killing, occurring after caspase activation. In addition, death receptor mediated killing 
can take longer than 4 hours to be observed, due to several reasons. NK cells can 
induce Fas expression in previously Fas negative tumors. NK cells can also be 
induced to express cell-surface FasL upon ligation of their activating receptors, such 
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as NKG2D (210). Thus, it can take several hours for Fas to be expressed, and then 
Fas-mediated tumor lysis. Further, IFNγ can sensitize cells to death receptor 
mediated killing by upregulating caspase 8 expression in the target cells, a requisite 
for death receptor mediated lysis (211-215). Thus, longer-term cytotoxicity assays 
will be important for providing a more thorough evaluation of the ability of ReNK cells 
to mediate tumor lysis through multiple pathways. 
Unexpectedly, we observed significantly increased killing by ReNK cells in the 
presence of TGFβ compared to no TGFβ against MG63 and D283. We did not 
observe significant changes in NKG2D, TRAIL, Granzyme A, Granzyme B, or 
Perforin in ReNK cells rested overnight plus or minus TGFβ. therefore, it is unlikely 
that overnight TGFβ treatment is increasing ReNK cell killing by directly affecting the 
NK cells. Alternatively, TGFβ may be sensitizing the tumor cells to NK cell lysis. In 
fact, TGFβ has been well-described to inhibit proliferation and to induce apoptosis in 
several cell types (216, 217). Since TGFβ does not inhibit ReNK cell killing, this 
effect on tumor cell sensitization is evident in ReNK cell lysis but not in Standard NK 
cells. 
 Interestingly, TGFβ retained its’ ability to suppress NK cell IFNγ secretion 
against MG63 and HOS even when SMAD3 is not present. This suggests a SMAD3-
independent mechanism of IFNγ suppression that could be mediated either through 
SMAD2 or by non-canonical TGFβ signaling. This finding is consistent with previous 
studies in primary NK cells demonstrating that both SMAD2 and SMAD3 can 
separately inhibit T-bet expression. Inhibition of T-bet decreases IFNγ secretion 
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(100). Future studies should better understand SMAD2 versus SMAD3 function and 
regulation of their expression in NK cells.  
 Receptor expression was significantly altered after expansion in both 
Standard and ReNK cells. NKG2D, which was inhibited by TGFβ during expansion, 
was significantly increased after expansion corresponding to removal from TGFβ. 
This effect may represent a compensatory response from TGFβ suppression of 
NKG2D, or be indicative of increased STAT3 activity, as STAT3 is important for 
optimal NKG2D expression (218). Surprisingly, Granzyme B expression decreased 
in both Standard and ReNK cells after expansion. However, Granzyme B was 
decreased to a much greater degree in ReNK cells with only 60% of ReNK cells 
expressing Granzyme B. Nonetheless, cytotoxicity of ReNK cells after expansion in 
the persistent culture was significantly increased compared to Standard NK cells 
even against previously resistant tumors (D283).  
There are several possible explanations for increased cytotoxicity in the 
absence of Granzyme B. These include FasL, TRAIL, TNFα-mediated apoptosis, or 
IFNγ tumor sensitization. Despite little to no detectable FasL expression after 
expansion, FasL is readily stored in the granules in NK cells and CD8+ T-cells and 
released upon degranulation or secreted (68, 210, 219, 220). In γδ T-cells, NKG2D 
ligation stimulates the release of soluble TRAIL, which was an important pathway of 
cytotoxicity against certain tumor targets (221). Another alternative is cytotoxicity 
through TNFα or IFNγ as ReNK cells have significantly increased cytokine 
production. Both membrane-bound and soluble TNF-α can mediate apoptosis-
directly by binding to TNFRs on target cells (222, 223). Recently, our lab reported 
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that IFNγ can sensitize tumors to NK cell lysis by upregulating ICAM-1 on the tumor 
but this effect is cell-line dependent (224). IFNγ can also enhance death receptor 
mediated killing (211-214). 
We choose to assess the ability of ReNK cells to produce IL-6, IFNγ, and 
TNFα, because these cytokines can both inhibit TGFβ and conversely, TGFβ can 
inhibit the production of IFNγ and TNFα. In a spontaneous canine model, IL-6 
secretion neutralized TGFβ, causing restoration of NK-like tumor killing (199). In 
addition, TGFβ stimulates IL-6 production (225). We found a similar effect in ReNK 
cells, which had increased IL-6 production without stimulation and increased IL-6 
anti-tumor production against MG63. IL-6 production has been reported to decrease 
membrane-bound TGFβ through STAT3 and to stimulate NK cell production of IL-17 
(226, 227).  We found evidence for this effect in ReNK cells which had significantly 
decreased mRNA for TGFβ1 and a trend towards increased IL-17 mRNA (3 out of 4 
donors expressed detectable IL-17). However, decreased TGFβ1 may represent a 
feedback mechanism to decrease TGFβ production by NK cells already receiving 
exogenous TGFβ. Both HOS and MG63 stimulated less IL-6 production than when 
the NK cells were unstimulated; therefore, it is unlikely that IL-6 is contributing to the 
enhanced anti-tumor function observed in ReNK cells. Decreased IL-6 production in 
the presence of tumor may be due to ligation of CD158b (KIR2DL2/3), with HLA-C 
on the tumor which inhibits IL-6 production (228).  
Surprisingly, we found remarkably increased anti-tumor IFNγ and TNFα 
secretion in ReNK cells compared to Standard NK cells both with and without TGFβ 
treatment. Previous studies have demonstrated that SMAD3 deletion increases 
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baseline IFNγ production, therefore, it is likely that a similar mechanism is occurring 
in ReNK cells which do not express SMAD3 (177). TGFβ is reported to inhibit TNFα 
production in primary NK cells (87); however, we did not observe decreased TNFα 
secretion in either Standard or ReNK cells with TGFβ treatment. Nonetheless, ReNK 
cells had significantly increased secretion of TNFα both plus and minus TGFβ 
treatment compared to Standard NK cells. Regulation of TNFα production is less 
well-understood. TNFα may be positively regulated through combined IL-21 and 
TGFβ signaling, such as through increased STAT3, since IL-21/STAT3 expanded 
NK cells have increased TNFα secretion compared to IL-15/STAT5 expanded NK 
cells (66). On the contrary, TNFα upregulation in ReNK cells may be indirectly 
promoted by IFNγ. IFNγ promotes IRF-1 and IRF-8 which, in turn, increase TNFα 
secretion (229). Yet another alternative is increased activation of TACE/ADAM17. In 
NK cells, TACE is responsible for cleaving CD16 and TNFα from the cell surface. In 
fact, inhibition of TACE, decreases TNFα secretion, and TGFβ is reported to activate 
TACE. TGFβ activated TACE also cleaves TGFβR1 from the cell surface (230-233). 
Given the decreased CD16 expression observed in TGFβ treated NK cells, and the 
increased TNFα secretion in ReNK cells, it will be interesting to determine if TACE is 
contributing to ReNK cell function. 
We observed increased expression of SMAD6, an inhibitory SMAD. SMAD6 
inhibits BMP signaling (e.g. BMPR1A/ALK-3 & BMPR1B/ALK-6), and can also inhibit 
non-canonical TGFβ signaling through TGFβ induced TRAF6-TAK1-p38 MAPK/JNK 
(187, 188, 234). We observed a slight but significant decrease in mRNA levels of 
TAK1 and of TAB1, which acts downstream of TAK1. Paradoxically, TAK1 inhibition 
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decreases NK cell cytotoxicity and cytokine production (235), whereas ReNK cells 
have increased NK cell cytokine secretion. However, TAK1 inhibition in NK cells was 
studied in the context of NKG2D signaling, raising the possibility that the role of 
TAK1 as an enhancer or suppressor of NK cell activity is dependent upon the 
stimuli. TAK1 could be contributing to the decreased killing by ReNK cells against 
MG63, HOS, and D283. In tumor cells, TAK1 is necessary for TGFβ to mediate 
growth inhibition, thus, decreased TAK1 levels may promote proliferation of ReNK 
cells in the presence of TGFβ (188). In line with this observation, we also observed 
significantly decreased Rbl2 expression which also mediates TGFβ-induced growth 
arrest. Thus, ReNK cells are able to downregulate TGFβ growth inhibitory target 
genes (236). Future studies are needed to better understand the effect of the non-
canonical TGFβ pathways on NK cell function.  
Taken together, a possible explanation for increased NK cell function in ReNK 
cells may be due to an upregulation of STAT3 activity and a downregulation of 
SMAD3 caused by four potential mechanisms- 1) increased IL-21 signaling due to 
upregulation of IL-21R expression 2) combined IL-21 and TGFβ signaling promoting 
sustained STAT3 activity 3) increased STAT3 due to decreased SMAD3 and 4) 
promotion of STAT3 activity by SMAD2. Future experiments comparing NK cells 
from IL-15 (which signals primarily through STAT5) versus IL-21- mediated 
expansion would provide clarity on whether IL-21/STAT3 is in fact necessary for the 
generation of ReNK cell phenotype. Even though ReNK cells have decreased 
cytotoxicity at the end of expansion against some cell lines, they have great promise 
for improving NK cell therapy as murine models have demonstrated that SMAD3-/- 
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NK cells have enhanced in vivo anti-tumor function. Further, ReNK cells have 
increased retention of anti-tumor function after expansion. 
Chapter 5: General Discussion and Future Directions 
5.1 Dissertation Summary 
 In summary, this project improves adoptive NK cell therapy for OS in 2 
different ways. First, through the development of a novel canine specific NKp46 
antibody which enabled more extensive characterization of canine NK cells. The 
expansion of canine NK cells allows for the testing of NK cell therapy for OS in 
canines. To the best of our knowledge, this is the only large animal model with 
spontaneous cancer development in which syngeneic NK cells can be expanded to 
clinically relevant numbers. This model is likely to be important for the pre-clinical 
testing of genetically modified NK cells and of ReNK cells. Second, we also describe 
a novel non-genetic method for the ex vivo generation of human NK cells with 
reduced sensitivity to TGFβ and improved anti-tumor function.  
 We identified canine NK cells as CD3-/NKp46+ cells that have phenotypic and 
functional homology to human NK cells. Phenotypically, they express all of the 
NCRs, and CD16, along with Granzyme B and Perforin. Like human NK cells, they 
can be subdivided into NKp46 positive and negative NK cell subsets that have 
altered CD16 expression. Functionally, canine NK cells kill without prior sensitization 
against several tumor targets- OS, melanoma, and thyroid adenocarcinoma; and 
secrete the prototypic proinflammatory NK cell cytokines- IFNγ and TNFα. Further, 
similar to human NK cells, they proliferate rapidly (median= 20,283-fold in 3 weeks) 
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on K562 mbIL-21 feeder cells, the same feeder cell used for human NK cell 
propagation (237). 
 We describe here that expansion with IL-21 and TGFβ generates ReNK cells 
which display drastically enhanced anti-tumor IFNγ and TNFα secretion in both the 
presence and absence of TGFβ treatment. This increase in cytokine production 
persists for at least 33 days after expansion. In addition, ReNK cells have increased 
cytotoxicity after expansion compared to Standard NK cells. Recently, Romee et al. 
reported that cytokine-induced memory NK cells, which secrete significantly more 
IFNγ that non-memory NK cells but do not have improved cytotoxicity, had superior 
anti-tumor activity in murine models and in a clinical trial (67). These results highlight 
the importance and potential clinical impact that ReNK cells could have. 
5.2 Future Directions 
5.2.1 Pre-clinical Models for NK Cell Therapy 
 The development of a canine NK cell expansion protocol that is nearly 
identical to the human NK expansion platform has implications for the study of 
cancers outside of OS. Companion animal trials can be used to test the efficacy of 
novel NK cell therapies quickly in canine cancers with high homology to the 
corresponding human cancer such as OS, melanoma, leukemia, and lymphoma. 
The canine model is especially well-suited for the testing of new NK cell therapies in 
pediatric cancers, since pediatric cancers are relatively rare leading to slow accrual 
in clinical trials. Further, canine cancers progress quicker than cancers in humans 
allowing for new therapies to be tested and treatment efficacy to be assessed in less 
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than a year instead of in 5-10 years in human trials. Studies such as these directly 
benefit both canine and humans by providing an opportunity to immediately improve 
survival in canines and to aid in the design of human clinical trials and selection of 
the most promising therapies.  
 The canine model is ideal for testing NK cell therapies with unknown risk 
profiles. These include genetically modified NK cells, NK cell injections into the 
brain, and ReNK cells. Although ReNK cells are not genetically modified, their 
relative resistance to TGFβ combined with the importance of TGFβ in preventing 
autoimmunity renders it particularly important to test ReNK in an animal model with 
an intact immune system prior to human clinical trials. However, neither SMAD3-/- or 
TGFBR2-/- murine NK cells have caused autoimmune disease in murine models, and 
in fact, SMAD3-/- NK cells have demonstrated superior tumor control (174, 177). 
Since we have not been successful in ex vivo mbIL-21 expansion of murine NK 
cells, the canine model is even more valuable. 
 Other areas where the canine model can directly benefit NK cell therapy 
include the measurement of NK cell persistence and trafficking. To facilitate imaging 
and NK cell tracking, labeling agents such as 19 Fluorine can be used to label 
expanded NK cells before infusion into the canine patient. MRI scans can be added 
to assess whether the NK cells trafficked to the tumor site and their persistence in 
the recipient’s blood. Due to the larger size of canines compared to mice, regular 
blood draws are feasible enabling the measurement of persistence and function of 
adoptively transferred NK cells. These findings can then be used to correlate with 
disease progression or treatment outcomes. In addition, due to the high mortality 
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rate of canine cancers, post-mortem tissues can be readily obtained and used to 
determine the localization of NK cells within the tumor microenvironment and the 
phenotype of tumor-infiltrating NK cells.  
5.2.2 Inhibitory Receptors in Canine NK Cells 
 The development of the canine specific NKp46 antibody allows for further 
study of NK cell biology in canines, which has previously not been feasible. 
Specifically, it is not known how canine NK cells recognize non-malignant cells. 
Determination of non-malignant and/or self- cells is by binding of MHC to the KIR 
family of receptors in humans or Ly49 family in mice. The canine genome has only 
one copy of Ly49 (compared to several copies in mice) and there are several 
problems raised by the canine Ly49 sequence. First, the Ly49 family in mice 
includes both activating and inhibitory receptors, and it is not known if canine Ly49 is 
an inhibitory or an activating receptor. Second, canine Ly49 does not have a 
conserved cysteine residue, which is believed to be necessary for function (147). 
Thus, canine Ly49 may not code a functional protein. Our PCR data found Ly49 to 
be barely detectable, with Ct values on expanded canine NK cells around 39 cycles. 
This extremely low level of detection raises the possibility that the Ly49 transcript 
may not encode a protein of functional consequence in canine NK cells.  
In addition, some reports state that canines have KIR, the inhibitory receptors 
in humans. However, no data is made available to substantiate this statement and 
no KIR sequence can be found in the publicly available canine genome (148). 
However, the published canine genome is limited to only the standard poodle and 
boxer, with evidence that this sequenced 99% of the genome (238, 239). Due to the 
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considerable heterogeneity within canines, there exists a significant possibility of 
breed-to-breed heterogeneity in canine NK cell receptors, such that other breeds 
may express more Ly49 copies and/or KIR that was not found in the published 
genomes.  
 Other NK inhibitory receptors in mice and humans include CD94 and 
NKG2A/B; however, the canine genome has no predicted transcript for NKG2A or 
NKG2B although there is a transcript for CD94. In human NK cells, CD94 must 
dimerize with a NKG2-family protein to transduce the signal, but without the 
transcript for NKG2-family proteins capable of dimerizing with CD94, there remains 
uncertainty as to what function canine CD94 serves (240, 241). We attempted to 
determine CD94 expression on canine PBMC and expanded cells with the 
commercially available antibody reported to cross-react with canine, but did not find 
any discrete staining (clone HP-3D9). PCR to determine the relative expression of 
CD94 in canine NK cells and the development of a CD94 blocking antibody could be 
beneficial in determining what the functional significance is of CD94. 
To further understand inhibitory receptors in canine, sequencing of the 
genome from several different dog breeds would aid in determining if there are 
breed to breed differences in inhibitory receptor expression. In addition, RNA 
sequencing on isolated canine NK cells would provide an unbiased screening on 
what genes are expressed in canine NK cells and their relative abundance. 
Additionally, the development of blocking antibodies to canine MHC would enable 
the determination of the functional consequences of blocking inhibitory receptor 
signaling in canine NK cells. If as expected, the blocking of canine Dog Leukocyte 
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Antigen (DLA) (canine orthologue to MHC) increased canine NK cytotoxicity, one 
could infer that a yet undetermined inhibitory receptor is functioning to inhibit canine 
NK cell function against cells expressing self. Improved clarity on inhibitory receptor 
signaling in canine NK cells could improve donor selection for the testing of adoptive 
NK cell therapies by allowing for the selection of donors that are missing self-
ligands. 
5.2.3 Canine NK Cells: Implications in Infectious Disease & Autoimmunity 
 The identification and characterization of canine NK cells has implications for 
the study of NK cell biology in areas outside of cancer, such as in infectious disease 
and autoimmune diseases. Canines are susceptible to developing many of the same 
ailments as humans including influenza, allergies, diabetes, rabies, and autoimmune 
diseases such as muscular dystrophy, X-linked severe combined immunodeficiency, 
systemic lupus erythematous among others (242-245). Using the canine NKp46 
antibody, a better understanding of canine NK cell biology in these ailments can be 
assessed. Given the propensity of specific dog breeds to develop different ailments 
(i.e. Retrievers and Lupus), canines are a beneficial model for determining whether 
changes in NK cell biology are affecting the development of various disorders. For 
example, NK cell function and phenotype can be compared between Retrievers with 
Lupus and without, and then compared to other dog breeds that are not susceptible 
to Lupus. The decreased heterogeneity within individual dog breeds can be 
exploited to determine what may be causative factors in diseases. This could lead to 
determining the underlying genetic changes within a breed that make certain breeds 
more susceptible to development of a disease, and could be directly applicable to 
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both veterinary and human biology. In addition, canines are susceptible to several 
viral and parasitic diseases such as parvovirus and heartworm that are not common 
in humans, but can be deadly in dogs. Given that NK cells are also potent killers of 
virally-infected cells, it would be of great interest to veterinary practice to determine 
whether viral diseases such as parvovirus are killed by canine NK cells.  
5.2.4 Antibody Generation 
 The development of the canine NKp46 antibody and subsequent identification 
of canine NK cells exemplifies the utility and ease of generating antibodies to study 
proteins of interest. The majority of antibody generation has focused on first 
identifying a novel cell type before constructing an antibody that identifies this new 
cell type. The approach described in this project takes the opposite approach of first 
identifying a protein of interest (e.g. canine NKp46), and then using the antibody to 
determine what cells are identified by the protein of interest. This approach has 
potential for facilitating quicker identification of novel cell types and better 
understanding of proteins. It can also be used in combination with genomic 
searching or RNA sequencing for highly expressed genes, and then generating 
antibodies to the proteins the gene encodes. Then, the new antibody can be used to 
determine both the cell subsets that express that protein and the function of that 
protein. For example, in studying canine NK cells, this approach could be applied to 
generate an antibody to canine Ly49 to better understand the cells that express 
Ly49 and its’ function. 
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5.2.5 TGFβ Resistance 
 The present project on ReNK cells raises several unanswered questions. 
First, the mechanism behind generation of TGFβ resistance and enhanced anti-
tumor function is unknown. Of particular interest is whether IL-21 is required for 
these effects. Since IL-21 and TGFβ cooperate to generate Th17 cells through 
prolonged STAT3 activation, it is possible that a similar Th17 development pathway 
can occur in NK cells (201, 246). Other alternative mechanisms include whether 
long-term TGFβ treatment alone downregulates SMAD3, causing TGFβ 
desensitization. However, since NK cells in cancer patients who have elevated 
serum TGFβ levels have reduced functionality, it is unlikely that TGFβ alone can 
generate a hyperfunctional NK cell. Another alternative is that another protein 
expressed on K562 feeder cells is cooperating with TGFβ to generate ReNK cells. 
The K562 feeder cell was engineered to express 41BBL along with IL-21, and K562 
are highly sensitive to NK cell lysis suggesting that they constitutively express other 
activating ligands that could cooperate with TGFβ to produce ReNK.  
In addition, it is not known why ReNK cells lose their relative resistance to 
TGFβ after 3 weeks of resting in low-dose IL-2. Given the striking loss of both 
SMAD3 RNA and protein in ReNK cells and SMAD3’s well-defined role in 
suppressing NK cell anti-tumor activity, we hypothesize this is due to a gain of 
SMAD3 protein. This would suggest that ReNK cells have transiently downregulated 
SMAD3 through either methylation of the SMAD3 locus or miRNA inhibition.  
It will be interesting to determine if ReNK cells are an artifact of ex vivo 
manipulation or if they are a subpopulation of NK cells that exist naturally and have 
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been selected through IL-21 and TGFβ expansion. It is likely that ReNK cells do 
constitute a subset of natural NK cells, as it is feasible to imagine situations where 
NK cells would be exposed to IL-21 and TGFβ concurrently such as in lymphoid 
tissues where NK cells would be exposed to IL-21 producing Th17 cells and follicular 
T-cells along with TGFβ from either regulatory T-cells or NK cell intrinsic production 
of TGFβ (247, 248). 
TGFβ is necessary for preventing autoimmune reactions, as TGFβ or 
TGFβRI/II knockout mice die of autoimmune disease at a young age (249). Further, 
expression of a dominant negative TGFβRII in CD8+ T-cells causes the 
development of lymphoma or lymphoproliferative disorders (250). Therefore, it is 
possible that infusion of ReNK cells could exacerbate autoimmune disease. In 
addition, the substantially increased secretion of IFNγ and TNFα could cause 
cytokine release syndrome. Both IFNγ and TNFα antagonize wound healing and NK 
cells are known to be present in wounds; therefore, ReNK cells may hinder proper 
wound healing by promoting excess inflammation through their secretion of IFNγ 
and TNFα (251-254). Although ReNK cells do not secrete cytokines in the absence 
of tumors, it will be necessary to determine their safety profile against non-malignant 
cells and their in vivo safety particularly in settings of bulky disease where their 
potent anti-tumor response could promote the development of cytokine release 
syndrome. 
` The generation of NK cells with relative resistance to TGFβ Resistant NK 
cells through combined long-term exposure to TGFβ and IL-21 raises the possibility 
as to whether NK cells can be generated that are resistant to other immune 
108 
 
suppressors. Since ReNK cells are SMAD3-, it is likely that they will be less sensitive 
to suppression by Activin A, which like TGFβ mediates its’ suppressive effects on NK 
cell cytokine production through SMAD2/3 (183). It would be interesting to determine 
if TGFβ resistant NK cells display selective resistance to TGFβ as would be 
expected, or if they are resistant to other suppressive pathways such as Tim-3, IDO, 
and hypoxia. The mechanism by which ReNK cells become resistant will help 
elucidate the likelihood that ReNK cells are also resistant to other means of 
suppression and if NK cells resistant to other suppressive proteins can be generated 
through a similar method. Specifically, if long-term exposure to TGFβ is sufficient to 
induce the development or selection of NK cells resistant to TGFβ’s effects, than 
long-term exposure to Tim-3 or IDO would be hypothesized to also select for NK 
cells resistant to Tim-3 and IDO. If so, the expansion of NK cells on different 
immunosuppressive factors could hold great potential for selecting for resistant NK 
cells.  
5.2.6 Development of TGFβ Resistant T-cells 
 The generation of ReNK cells raise the possibility that expanded T-cells could 
also be generated that are resistant to TGFβ, given that T-cells can also expand 
robustly on K562 feeder cells. In fact, the K562 feeder cell line used in the described 
studies was originally constructed to stimulate T-cell growth. In addition, IL-21 has a 
potent stimulatory effect on CD8+ T-cells (255). TGFβ is also highly suppressive to 
T-cells, causing upregulation of PD-1, decreased IL-2 and IFNγ production, 
decreased proliferation and cytotoxicity (105, 106, 198, 256). Given the similarities 
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between NK and CD8 T-cells, it is likely that CD8 T-cells could be made resistance 
to TGFβ and represents a promising area for improving T-cell therapy. 
 Since both IL-21 and TGFβ are highly implemented in the development of 
Th17 CD4 T-cells, the expansion of CD4 T-cells on K562 mbIL-21 feeder cells with 
TGFβ is likely to preferentially lead to an outgrowth of Th17 cells (246). This could 
represent a method of generating clinically relevant numbers of Th17 cells for 
therapeutic utility. Expanded Th17 cells could be beneficial in HIV, where they are 
preferentially depleted due to their expression of CCR5, the coreceptor for HIV. 
Depletion of Th17 cells in HIV disturbs intestinal mucosal integrity, leading to 
microbial translocation, and sustained immune activation (257). In fact, recovery of 
Th17 cell numbers by the administration of IL-21 to SIV-infected macaques 
decreased microbial translocation and immune activation. Therefore, if Th17 cells 
can be expanded with K562 mbIL-21 plus TGFβ, their adoptive transfer into HIV 
patients could be a beneficial new therapy (258).  
5.2.7 ReNK cells for Infectious Diseases 
 ReNK cells may have therapeutic benefit in other malignancies outside of 
cancer. Specifically, ReNK cells are specially poised for use in control of the 
parasite- Trypanosoma Cruzi (T. cruzi) which causes Chagas disease. T. cruzi 
requires expression of the TGFβ receptor and an intact TGFβ signaling pathway for 
infection (259). Since ReNK cells are SMAD3neg, they are likely resistant to infection 
by T. cruzi. NK cells have been demonstrated to be important in control of T. cruzi, 
infection, as depletion of NK cells renders mice more sensitive to T. cruzi infection. 
In addition, asymptomatic Chagas patients have increased NK cell numbers while 
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Chagas patients with cardiac myopathy have decreased NK cell numbers and 
expression of genes related to NK cell function such as Granzymes and Perforin 
(260, 261). Thus, adoptive transfer of ReNK cells could be ideal in repleting the 
reduced NK cells numbers in Chagas and resisting cell death by infection.  
5.2.8 Conclusion 
 In conclusion, we describe here two novel approaches towards improving 
treatment for OS patients, where survival has not improved in the last 30 years. The 
development of a novel anti-canine NKp46 antibody allows for improved 
characterization of NK cells and 20,000-fold expansion of canine NK cells on K562 
mbIL-21 will allow for NK cell therapy to be tested in canine OS. In fact, a similar 
expansion of canine NK cells is currently being used to test the effectiveness of 
intratumoral injections of canine NK cells after radiation in OS (UC Davis, R. Canter 
& W. Murphy). Second, we developed a non-genetic approach to generate NK cells 
with relative resistance to TGFβ, which is elevated in OS, and represents a 
mechanism of immune evasion by cancer. Most importantly, these ReNK cells have 
improved anti-tumor activity against OS. Together these two approaches hold 
promise for improving OS outcomes through NK cell therapy. 
Chapter 6: Materials & Methods 
This chapter is based upon Foltz, J. A., S. S. Somanchi, Y. Yang, A. Aquino-
Lopez, E. E. Bishop, and D. A. Lee. 2016. NCR1 Expression Identifies Canine 
Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells. 
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Frontiers in Immunology 7. with permission from NK and Innate Lymphoid Cell 
Biology- Frontiers in Immunology under the terms of the CC BY license. 
6.1 Peripheral Blood Mononuclear Cell Isolation 
Animal research was conducted with approval from the Institutional Animal 
Care and Use Committee at MD Anderson Cancer Center (00001532-RN00). 
Healthy canine blood was obtained from established animal colonies at the following 
locations: Animal Blood Resources International, Hemopet, and Texas A&M 
University (IACUC Protocol: 2014-0294). Healthy canine blood from UC Davis was 
exempted from IACUC approval. All blood from client-owned animals was obtained 
with informed consent and was consistent with the established guidelines for safe 
canine blood draws. Blood from canine patients with suspected osteosarcoma who 
had not received chemotherapy within 1 month was obtained with informed consent 
from UC Davis under Protocol 18315. Osteosarcoma diagnosis was confirmed with 
radiographs or biopsies. Two out of the seven canine patients presented with 
potential chondroblastic osteosarcoma, with one of the two patients presenting with 
disease with alternative diagnosis of chondrosarcoma. Four out of the seven 
patients were females with ages ranging from 2 to 13 years old. Osteosarcoma 
tumor sites were frontal bone (1), metatarsal (1), tibia (1), femur (1), radius (2), and 
ileal body (1). Canine blood was drawn into lithium heparin tubes and was diluted 
upon receipt 1:5 in HBSS before Ficoll separation and canine RBCs were lysed with 
RBC lysis buffer (Stem Cell Technologies, 07800) for 4 min on ice (36, 37). 
Experiments using discarded buffy coats from normal human red blood cell 
(RBC) donations were conducted under MD Anderson Cancer Center IRB 
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exemption PA13-0978 and Nationwide Children’s Hospital IRB Exemption. Both 
canine and human blood were processed using Ficoll Plus (GE Healthcare; 17-
1440-02), as described previously. Human NK cells were purified with RosetteSep 
Human NK Cell Enrichment Cocktail (Stem Cell Technologies, 15065).  
6.2 Cell Culture 
The canine cell lines OSCA8 (OS of the humerus, Jaime Modiano, University 
of Minnesota) and OSCA40 (OS of the femur, Jaime Modiano), Gray (OS lung 
metastasis, University of Wisconsin, Greg MacEwen), Abrams (OS, Ryan Roberts, 
Research Institute at Nationwide Children’s Hospital), OSCA-78 (femur OS, 
Kerafast, EMN004), and melanoma-12 (Carlos Rodriguez, UC Davis) were cultured 
in DMEM High Glucose (Hyclone, SH30243.FS) with 10% FBS (Hyclone, 
SH30071.03HI), Penicillin Streptomycin Amphotericin Antibiotics (Lonza, 17-745E), 
and HEPES (OSCA-78 only; Gibco, 15630-080). Canine thyroid adenocarcinoma 
(CTAC) (Ohio State University, George Krakowka) was cultured in RPMI 1640 
(Hyclone, SH30096.FS) with 10% FBS, Glutamax (ThermoFisher Scientific, 
35050061), and Antibiotics. Manin–Darby canine kidney cells (MDCK) (Sigma-
Aldrich, 84121903-1VL) were cultured in Eagles Minimum Essential Media (Hyclone, 
SH30244.FS) with 10% FBS, PSA, Glutamax, and 1% Minimum Essential Amino 
Acids (Sigma, M7145). All cell lines reported in this study were identified as canine 
origin by species-specific PCR and were unique from each other by canine STR 
fingerprinting (CellCheck Canine, IDEXX BioResearch). Only MDCK had an 
established genetic profile with which to compare, which matched the results 
obtained for our MDCK cell line. The OSCA8 cell line was reported as having been 
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derived from a male, but fingerprinting of our OSCA8 cell line showed only 
chromosome X (262). This could be caused by a loss of chromosome Y during 
culture over time. Cells were dissociated for cytotoxicity assays using enzyme-free 
Cell Dissociation Buffer, Hank’s Based (ThermoFisher Scientific, 13150016). NK 
cells were cultured in RPMI 1640 media plus Glutamax, 10% FBS, and antibiotics. 
All cells were routinely tested for Mycoplasma contamination using Lonza MycoAlert 
(Lonza, LT027-58) and found to be negative at all time points with the exception of 
melanoma-12. K562 feeder cells were derived by transducing K562, a chronic 
myelogenous leukemia cell line, with human 4-1BBL and membrane-bound human 
IL-21 (Clone9.mbIL21) as previously described (165).   
6.3 NK Cell Expansion 
Five million canine PBMC were cocultured with 106 K562 Clone9.mbIL-21 in 
at day 0 (1:2 ratio), and additional K562s were added at a 1:1 ratio at days 7 and 14. 
Medium was supplemented with 6.1 ng/mL recombinant canine IL-2 (rcIL-2) (R&D 
systems, 1815-CL), and fresh medium was added every 2–3 days. For human IL-2 
comparison expansions, human IL-2 was added at 100 IU/mL in place of canine IL-
2. The concentration of human IL-2 was based upon the dose of IL-2 used in 
previous publications on canine NK-like cells (138, 139, 263).   
For CD3 depletion experiments, canine PBMC was stained with CD3-FITC 
antibody and sorted for all PBMC that were CD3-negative. Sodium azide in CD3 
antibody was reduced using Amicon Ultra-0.5 mL Centrifugal Filter Units with 
Ultracel-50 Membrane (EMD Millipore, UFC505024). Expansion was done according 
to the previous protocol, comparing CD3-depleted PBMC to undepleted PBMC.  
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Fold expansion was calculated as the percentage of CD3−/NKp46+ cells 
within the lymphocyte gate of total PBMC. Null cell calculations were determined by 
subtracting the percentage of CD21 and CD14 expressing cells in the lymphocyte 
gate from the CD3− cell percentage. 
Purified primary human NK Cells were stimulated at Day 0 1:2 with K562 
mbIL-21 and 1:1 at Day 7. Standard expanded NK cells were supplemented with 50 
IU/mL recombinant human IL-2, and Resistant (ReNK) expanded NK cells received 
50 IU/mL IL-2 plus 10 ng/mL TGFβ (Biolegend, 580706). Fresh media and cytokines 
were added every 2-3 days. NK Cell Expansion was calculated based on the 
percentage of CD3-/CD56+ cells. 
6.4 Sequencing 
The sequence of canine NKp46 was verified with the following primers: 
Forward: 5′ ACTCACTGCCCTTCTCTTCC 3′, Reverse: 5′ 
CTAACTGTGGCCAGCACATC 3′ via RT-PCR with the following conditions Initial 
Denaturation: 94°C – 3 min, Denature: 94°C – 30 s, Annealing: 58°C – 30 s, 
Extension: 68°C – 1 min, Final Extension: 68°C – 5 min for 35 cycles using Platinum 
Taq DNA Polymerase High Fidelity (ThermoFisher Scientific, Cat: 11304-011) and 
dNTPs (ThermoFisher Scientific, Cat: 18427013). The PCR product was cloned into 
pCR2.1 Vector using TA cloning (ThermoFisher Scientific, K202020) and sequenced 
using Sanger-based sequencing on an ABI 3730 with M13 (-21) Forward and M13 
Reverse Primers. 
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6.5 NKp46 Antibody Production 
A mouse monoclonal antibody specific to canine NKp46 was constructed by 
first confirming the expression and sequence of NKp46 in expanded canine lineage 
negative (CD3−/TCR−/CD21−/CD14−) cells, using primers which covered 940/955 
bp of canine NKp46 (NM_001284448.1). The sequence obtained matched the NCBI 
database sequence (data not shown). A chimeric protein composed of the signal 
sequence of human granulocyte-macrophage colony-stimulating factor (GM-CSF, 
NP_000749.2; aa: 1–17), the extracellular domain of canine NKp46 as determined 
using Phobius protein prediction software (NP_001271377.1; aa: 21–255), and 
murine CD8α extracellular and transmembrane regions (NP_001074579.1; aa: 28–
247) was constructed and synthesized using Life Technologies (custom order). This 
construct was ligated into the MigR1 vector (Provided by Patrick Zweidler-McKay), 
and virus was produced using GP2-293 packaging cells (Clontech, 631530) with 0.8 
μg pVSV-G packaging vector (Clontech), 10 μL Lipofectamine 2000, and 4 μg of the 
NKp46-MigR1 vector or Empty vector per well of a six-well plate. Supernatant was 
collected after 40 h, spun down, and added to L-cells (ATCC, CRL-2648) along with 
8 μg/mL polybrene. Cell surface expression of the chimeric NKp46 protein was 
verified through flow staining with anti-mouse CD8α antibody (BD Biosciences; 
561093) and GFP. BALB/C mice were immunized via footpad with L-cells 
expressing NKp46 fusion protein for 33 days (NKp46:L-cells) as previously 
described. (264) 
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6.6 Flow Cytometry 
Blocking was performed in blocking buffer (50% FBS/PBS) with 0.1 mg of dog 
gamma globulin (Jackson ImmunoResearch, 0004-000-002) per 1,000,000 cells. 
Cells were stained with 200 ng/1,000,000 cells of mouse anti-canine NKp46 Clone 
48A (isotype: IgG2a) or unconjugated TCRαβ/TCRγδ for 30 min, followed by goat 
anti-mouse IgG RPE (Jackson ImmunoResearch, 115-116-146) in 50% FBS/PBS, 
and finally with anti-canine TCRαβ/γδ (FITC/Alexa Fluor 488 when indicated; Peter 
Moore, UC Davis) and commercially available antibodies (Biorad) to canine CD3 
(MCA1774F; clone CA17.2A12), CD8α (MCA1039A700; clone YCATE55.9), CD4 
(MCA1038PECY7; clone YKIX302.9), CD21 (MCA1781A647; clone CA2.1D6), CD5 
(MCA1037APC; YKIX322.3), and anti-human CD14 (MCA1568A647, 
MCA1568A700; TÜK4). Cell events were acquired on a LSR Fortessa. Flow 
cytometry gating was determined using cells stained with secondary only and single 
color controls were analyzed using FlowJo 7.6.5/10. 
Staining of human NK cells was conducted as described above but without 
dog gamma globulin. Transcription factors were stained using the Transcription 
Factor Buffer Kit (BD Biosciences, 562725). All other intracellular flow cytometry was 
done using the BD Cytofix/Cytoperm Fixation/Permeabilization Kit with GolgiStop 
(BD Biosciences, 554715). Antibodies for the following proteins were used to assess 
NK phenotype and function: CD3 PeCy7/APC-H7 (clone SK7), CD56 FITC, NKG2D 
Pe-CF594, TRAIL PE/APC, FasL PE, NKp30 PE/Alexa Fluor 647, Granzyme A 
APC, Granzyme B BV510, Perforin BV421, DNAM-1 BV711, CD107a BV510, IFNγ 
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APC, TNFα BV421, IL-6 PE, CD16 PE, T-bet APC, GATA3 BV421, RUNX3 PE, and 
Tonbo Ghost Dye 510/710. 
6.7 Cell Sorting 
Canine cells were sorted on a FACSAria Sorter at the flow cytometry core 
facility (UT MD Anderson Cancer Center) using four-way purity with post-sort purity 
verification for expression of CD3 and NKp46 to generate ≥99.5% pure populations 
of CD3−/NKp46+, CD3−/NKp46−, CD3+, and CD3− cells when indicated. 
6.8 Luminex 
Luminex assays were done, as described previously, using tissue culture 
supernatant from 2 × 105 sorted, CD3−/NKp46+, CD3−/NKp46−, or CD3+ expanded 
cells cocultured for 6 h at 37°C with rcIL-2 or rcIL-2 plus 4 × 105 K562 Clone9.mbIL-
21 irradiated feeder cells with the CCYTOMAG-90K Canine Cytokine Chemokine 
Panel (EMD Millipore, CCYTMG-90K-PX13) on a Bioplex-200 using Bioplex 
Manager 6.0 Software (Biorad, USA) (41). Cytokine secretion with coculture with 
K562 Clone9.mbIL-21 feeder cells was normalized by subtracting cytokine secretion 
in IL-2 only. 
6.9 Cytotoxicity Assays 
Canine CD3−/NKp46+ were sorted when necessary to be ≥95% pure. 
Comparison of CD3−/NKp46+, CD3−/NKp46−, and CD3+ expanded cells were sorted 
as described, rested overnight in IL-2, and cytotoxicity assays with calcein-AM 
based method were conducted in at least duplicate using 4 µg of calcein 
AM/1,000,000 target cells (265).   
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Calcein assays with human cell lines were done similarly with the exception of 
3 µg calcein AM/mL/1,000,000 target cells in complete media. NK cells were 
prepared for cytotoxicity assays by resting overnight in either human IL-2 alone or 
IL-2 (50 IU/mL) with 10 ng/mL soluble TGFβ (Biolegend). Calcein assays were 
conducted in the same cytokines as the NK cells were rested in overnight. 
6.10 Intracellular Functional Flow Cytometry 
 To determine degranulation by CD107a expression and intracellular cytokine 
production in response to tumors, 300,000 NK cells were co-cultured in a 96-well 
round-bottom plate with 60,000 tumor cells (5:1 E:T ratio) or no target for a control in 
200 µl media as described for cytotoxicity assays. One µl of monensin was added to 
each sample along with CD107a at the beginning of the assay. Plates were spun 
down at 100 g x 2 minutes to promote cell-cell contact, and placed in a 37oC 
incubator for 3 hours. After 3 hours, media was removed and staining began for cell 
surface and intracellular proteins as detailed. 
6.11 Cytometric Bead Array (CBA) 
 To determine NK cell release of IFNγ and TNFα, NK cells were cultured as 
described for intracellular functional flow cytometry with the exception of monensin 
and CD107a antibody. After 3 hours, supernatant were collected and frozen at -70oC 
until use. On the day of the CBA assay, supernatants were thawed and 50 µl of 
undiluted supernatant was used according to manufacturer’s instructions for the BD 
CBA Soluble Protein Master Kit and IFNγ and TNFα Flex Set. The analytes had a 
limit of detection of 10 pg/mL. At least 300 events per analyte was acquired on a BD 
LSR Fortessa. Geometric mean for each analyte was determined in Flow Jo v. 10.1 
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and unknown samples were interpolated using a standard curve with R2 ≥ 0.99 from 
known standards. Negative cytokine measurements were graphed as 0 pg/mL. 
6.12 RT-PCR/qPCR 
RNA was isolated from canine expanded cells using RNAeasy Kit, 
QiaShredder Columns, and RNAase-Free DNase Set (all Qiagen, 74104, 79654, 
79254), and cDNA was synthesized using Omniscript RT Kit (Qiagen, 20511) with 
RNase inhibitor (New England Biolabs, M0307S) and Oligo(dt)20 (ThermoFisher 
Scientific, 18418-020). RT-PCR and qPCR reactions were performed on Roche 480 
(Roche, USA) using Power Up Sybr Green Master Mix (ThermoFisher; A25742) or 
TaqMan Universal PCR Mastermix for qPCR for CD16 (ThermoFisher Scientific, 
4304437) for 40 cycles. All qPCR was done in duplicate with at least three different 
donors. Semi-quantitative RT-PCR reactions were run on five different donors with 
100 ng cDNA per sample and 6× DNA loading dye, and products were verified on a 
1.5% agarose gel with TAE buffer and GelRed Nucleic Acid Stain (Phenix, RGB-
4103) and 100 bp DNA Ladder (New England Biolabs, N3238S). Gels were imaged 
on BioRad ChemiDoc Touch Imaging System (BioRad, USA) for Faint Bands and 
analyzed using Image Lab 5.2.1. The following enhancements were uniformly 
applied to all gels (High: 65535, Low: 34, Gamma: 0.43). 
PCR cycling conditions were as followings: UDG activation: 50°C – 2 min, 
Polymerase Activation: 95°C – 2 min, Denature: 95°C – 15 s, B-actin, NKp46, 
NKp30, Granzyme B, and Perforin – Anneal/Extend: 62°C – 1 min; B-actin, Ly49, 
and CD16 – Anneal: 54°C – 15 s, Extension: 72°C – 1 min; B-actin, DNAM-1, 
NKp30, NKp44, NKG2D, and NKp80 at the same conditions as Ly49 and CD16 with 
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the exception of Annealing at 59°C. Primer sequences for NKp30, NKG2D, Perforin, 
and Granzyme B were published and verified previously (22). Primers for all other 
genes were made using Blast Primer software and Primer 3 with predicted specificity 
verified by Blast, as follows: Ly49: Forward-5′ TGGAAATGGGTTGACACTGA 3′, 
Reverse-5′ CTTTGGAAGGAGGCAGACAA 3′; NKp46: Forward-5′ 
CCGCATCCCAAAAATGACCC 3′, Reverse-5′ GGGCCTATGGGAAACTCCAC 3′; 
NKp80: Forward-5′ TCCCTGTCCTTACTGGTTTCTC 3′, Reverse-5′ 
TATTTGAGCCATTCCGATG 3′; CD16: Forward-5′ CAGTGGAGAGTACAGGTGCC 
3′, Reverse-5′ CCCTGCAGAAGTAGGAGCC 3′; DNAM-1: Forward-5′ 
AATGTCACGCTCACCTGTCA 3′, Reverse-5′ CGGTAAAGTCCCGAGTCAGA 3′; 
NKp44: Forward-5′ GAAGGAGGAAGACTCGGGATA 3′, Reverse-5′ 
GAAGGGGTGATGGTGGTAGA 3′; and B-actin: Forward-5′ 
CGAGCATCCCCAAAGTTCTA 3′, Reverse-5′ ATTCTCTTTCCCTCCCCTGT 3′. 
Primer specificity was verified by Melt Curve Analysis and agarose gel 
electrophoresis. Primer product sequences for new primers were verified using 
Qiaquick Gel Extraction Kit (Qiagen, 28704) and sequencing, as described 
previously. Primers were synthesized by Sigma-Aldrich. For qPCR for CD16, 
TaqMan Universal PCR Master Mix was used with B-actin (ThermoFisher Scientific, 
Catalog #: 4453320, Assay ID: Cf03023880_g1) and CD16 probes (ThermoFisher 
Scientific, Catalog #: 4448892 Assay ID: Cf02645051_m1) for 40 cycles according to 
the TaqMan Universal PCR Master Mix protocol. qPCR was determined using the 
2−ΔΔCt2−ΔΔCt method and normalized to B-actin, and relative to CD3−/NKp46+ 
cells from the same donor. 
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RNA from fresh, never frozen, Day 14 expanded human NK cells was done 
as described for canine. cDNA was made using the high throughput cDNA kit. PCR 
for the TGFβ pathway was done using Taqman Fast PCR Mastermix and Human 
Fast 96-well TGFβ Pathway Array (ThermoFisher, 4418742) on an Applied 
Biosystems 7900HT. 
6.13 Mass Cytometry 
Antibodies for mass cytometry were labeled with heavy metals using Maxpar-
X8 labeling reagent kits (DVS Sciences) according to manufacturer’s instructions 
and titrated for determination of optimal concentration. The antibodies and their 
respective heavy metal labeling include CD314/NKG2D-150Nd (Biolegend, 320802), 
CD3-151Eu (BioLegend, 300443), CD335/NKp46-154Sm (BioLegend, 331902), 
CD56-162Dy (BD, 559043), CD336/NKp44-163Dy (BioLegend, 325102), 
CD337/NKp30-164Dy (BioLegend, 325202) CD16-165Ho (DVS, 3165001B), 
CD159a/NKG2A-166Er (R&D, MAB1059), CD226/DNAM1-167Er (BioLegend, 
337102), and CD159c/NKG2C-169Tm (R&D, MAB1381). Frozen primary and K562 
Clone9.mbIL-21 expanded human NK cells were thawed 1 day prior to staining to 
allow for NK cell recovery overnight. After overnight recovery, 1.5 × 106 cells were 
stained with 2.5μM cell ID cisplatin (Fluidigm, 201064) in serum-free RPMI for 1 min 
for identification of viable populations. Subsequently, CyTOF staining was 
performed, as described previously, with the following minor modification: staining 
was performed in 5% FBS/0.01% sodium azide buffer in PBS (266). Data were 
acquired on the CyTOF instrument (DVS Sciences). 
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6.13.1 Clustering Analysis 
Clustering analysis of mass cytometry data was performed using spanning-
tree progression analysis of density-normalized events (SPADE V3.0) software 
(267). Markers used for clustering of data were CD56, NKp46, NKp30, NKp44, 
NKG2A, NKG2C, and NKG2D. 
6.14 Western Blotting 
 Day 14 expanded NK cells were lysed with RIPPA buffer. Protein yield was 
quantified with a Bradford assay. 20 µg of protein was loaded onto a gel. All 
antibodies used were from Cell Signaling. 
 Quantification of STAT3 levels was done using ImageJ software. The ratio of 
pSTAT3 to total STAT3 was calculated using the IL-21 treated NK samples. Total 
STAT3 to GAPDH calculations were done using untreated NK cell samples, since 
total STAT3 levels were determined to be affected by the degree of pSTAT3. 
6.15 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6.0 or 7.0. Luminex 
assays were analyzed with unpaired t-tests and Holm–Sidak method for multiple 
comparisons. Paired t-tests were run for the following: cytotoxicity assays between 
NK and T-cells or Null Cells, qPCR, comparison of NKp46+ and NKp46− human NK 
cell phenotype, and all TGFβ analysis. Comparison between healthy and OS-
bearing canines’ percent NK cells and expansion used the Mann–Whitney test. All 
other statistical analyses were unpaired Student’s t-tests (all two-tailed). Human 
versus canine IL-2 analysis used a one-tailed Wilcoxon-matched pairs test. 
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Correlations were done using the Spearman r test. p Values less than 0.05 were 
considered significant. 
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Appendix A. Screening of NKp46 Hybridomas with ELISA against L-cells 
expressing Canine NKp46. Dilutions are from L to R: Concentrate, 1:15, 1:225. 
ELISA was done by MD Anderson Monoclonl Antibody Core. 
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Appendix B. TGFβ Pathway Genes Assessed on TaqMan Array 
Gene p-value Mean ± SD 
ACVR1 0.17 1.3 ± 0.3 
ACVR1B 0.17 2.0 ± 1.1 
ACVR1C 0.21 2.8 ± 2.3 
ACVR2A 0.73 1.2 ± 0.8 
ACVR2B 0.95 1.0 ± 0.5 
AMH 0.38 5.4 ± 8.6 
AMHR2 0.47 1.8 ± 1.9 
BMP2 0.79 0.8 ± 1.2 
BMP3 N/A N/A 
BMP4 0.07 0.6 ± 0.3 
BMP5 N/A N/A 
BMP6 0.03 0.3 ± 0.3 
BMP7 0.2 3 ± 2.5 
BMP10 N/A N/A 
BMP15 N/A N/A 
BMPER 0.37 7.7 ± 12.8 
BMPR1B N/A N/A 
BMPR2 0.55 1.1 ± 0.3 
CDH1 NA/ N/A 
CHRD N/A N/A 
CREBBP 0.15 0.9 ± 0.2 
CUL1 0.45 1.9 ± 2.1 
DCN 0.54 1.5 ± 1.3 
E2F4 0.36 0.9 ± 0.1 
E2F5 0.57 1.2 ± 0.7 
EP300 0.05 0.8 ± 0.1 
FMOD 0.02 0.2 ± 0.3 
FNTA 0.48 1.2 ± 0.5 
FST 0.07 79.3 ± 56.8 
GDF2 N/A N/A 
GDF3 N/A N/A 
GDF5 0.23 8.7 ± 7.9 
GDF7 0.04 0.2 ± 0.3 
GDF9 0.51 1.4 ± 1.0 
GDF10 N/A N/A 
GDF11 0.3 1.3 ± 0.5 
GDF15 0.4 14.9 ± 28.0 
HIPK2 0.58 0.8 ± 0.5 
IFNG 0.38 2.1 ± 2.5 
IL17F 0.09 4.4 ± 1.9 
IL6 0.81 1.1 ± 1.0 
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INHA N/A N/A 
INHBA 0.12 0.6 ± 0.4 
INHBB 0.41 7.7 ± 11.1 
INHBC 0.98 1.0 ± 0.6 
INHBE 0.02 0.3 ± 0.3 
LEFTY1 0.46 0.7 ± 0.7 
LEFTY2 0.0031 0.5 ± 0.1 
LTBP1 0.54 1.3 ± 0.8 
LTBP2 0.04 0.3 ± 0.4 
LTBP3 0.05 0.9 ± 0.1 
LTBP4 0.12 1.5 ± 0.5 
MAP3K7/TAK1 0.02 0.7 ± 0.1 
MAP3K7IP1/TAB1 0.003 0.7 ± 0.1 
MAPK1 0.78 0.9 ± 0.4 
MAPK3 0.41 1.8 ± 1.6 
MSTN 0.19 8.1 ± 8.3 
NODAL N/A N/A 
NOG 0.1 0.5 ± 0.4 
PPP2CA 0.47 1.2 ± 0.4 
PPP2CB 0.81 1.0 ± 0.3 
RBL1 0.57 1.4 ± 1.1 
RBL2 0.0035 0.8 ± 0.1 
RBX1 0.68 0.9 ± 0.3 
RHOA 0.57 0.9 ± 0.3 
ROCK1 0.94 1.0 ± 0.5 
ROCK2 0.87 1.0 ± 0.5 
SKP1 0.76 1.1 ± 0.6 
SMAD1 0.03 0.6 ± 0.2 
SMAD2 0.88 1.0 ± 0.4 
SMAD3 <0.0001 0.03 ± 0.01 
SMAD4 0.91 1.0 ± 0.3 
SMAD5 0.12 1.2 ± 0.2 
SMAD6 0.0074 6.3 ± 1.6 
SMAD7 0.33 1.2 ± 0.4 
SMAD9 0.24 10.7 ± 13.2 
SMURF1 0.4 1.5 ± 0.9 
SMURF2 0.06 1.7 ± 0.5 
SP1 0.71 1.0 ± 0.2 
STUB1 0.07 0.8 ± 0.2 
TFDP1 0.37 1.8 ± 1.4 
TGFA 0.35 26.6 ± 46.1 
TGFB1 0.002 0.7 ± 0.1 
TGFB2 0.48 2.0 ± 2.4 
TGFB3 0.04 0.7 ± 0.2 
TGFBR1 0.17 0.8 ± 0.3 
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TGFBR2 0.8 1.1 ± 0.5 
TGFBR3 0.002 0.2 ± 0.1 
TGFBRAP1 0.64 0.9 ± 0.3 
TNF 0.11 0.7 ± 0.3 
TSC22D1 0.84 1.1 ± 0.9 
ZFYVE9 0.54 1.5 ± 1.4 
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